<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients - Vidal, L - 2013 | Cochrane Library</title> <meta content="Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients - Vidal, L - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003992.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients - Vidal, L - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003992.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003992.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients" name="citation_title"/> <meta content="Liat Vidal" name="citation_author"/> <meta content="Beilinson Hospital, Rabin Medical Center" name="citation_author_institution"/> <meta content="vidallit@yahoo.com" name="citation_author_email"/> <meta content="Itsik Ben dor" name="citation_author"/> <meta content="Beilinson Hospital, Rabin Medical Center" name="citation_author_institution"/> <meta content="Mical Paul" name="citation_author"/> <meta content="Rambam Health Care Campus" name="citation_author_institution"/> <meta content="Noa Eliakim‐Raz" name="citation_author"/> <meta content="Beilinson Hospital, Rabin Medical Center" name="citation_author_institution"/> <meta content="Ellisheva Pokroy" name="citation_author"/> <meta content="Beilinson Hospital, Rabin Medical Center" name="citation_author_institution"/> <meta content="Karla Soares‐Weiser" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Leonard Leibovici" name="citation_author"/> <meta content="Beilinson Hospital, Rabin Medical Center" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD003992.pub3" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/10/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003992.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003992.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003992.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Anti-Bacterial Agents [*administration &amp; dosage, adverse effects]; Chemotherapy-Induced Febrile Neutropenia [*drug therapy, mortality]; Injections, Intravenous; Neoplasms [*drug therapy]; Randomized Controlled Trials as Topic; Treatment Failure" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003992.pub3&amp;doi=10.1002/14651858.CD003992.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003992.pub3&amp;doi=10.1002/14651858.CD003992.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003992.pub3&amp;doi=10.1002/14651858.CD003992.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003992.pub3&amp;doi=10.1002/14651858.CD003992.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003992.pub3&amp;doi=10.1002/14651858.CD003992.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003992.pub3&amp;doi=10.1002/14651858.CD003992.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003992.pub3&amp;doi=10.1002/14651858.CD003992.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003992.pub3&amp;doi=10.1002/14651858.CD003992.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003992.pub3&amp;doi=10.1002/14651858.CD003992.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003992.pub3&amp;doi=10.1002/14651858.CD003992.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003992.pub3&amp;doi=10.1002/14651858.CD003992.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003992.pub3&amp;doi=10.1002/14651858.CD003992.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003992.pub3&amp;doi=10.1002/14651858.CD003992.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003992.pub3&amp;doi=10.1002/14651858.CD003992.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003992.pub3&amp;doi=10.1002/14651858.CD003992.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003992.pub3&amp;doi=10.1002/14651858.CD003992.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003992.pub3&amp;doi=10.1002/14651858.CD003992.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003992.pub3&amp;doi=10.1002/14651858.CD003992.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003992.pub3&amp;doi=10.1002/14651858.CD003992.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003992.pub3&amp;doi=10.1002/14651858.CD003992.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003992.pub3&amp;doi=10.1002/14651858.CD003992.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003992.pub3&amp;doi=10.1002/14651858.CD003992.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003992.pub3&amp;doi=10.1002/14651858.CD003992.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="zCmos3jT";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003992\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003992\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003992\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003992\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003992.pub3",title:"Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients",firstPublishedDate:"Oct 9, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro‐oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=zCmos3jT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003992.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003992.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003992.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003992.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003992.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003992.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003992.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003992.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003992.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003992.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2960 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003992.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/full#CD003992-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/full#CD003992-sec-0068"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/full#CD003992-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/full#CD003992-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/full#CD003992-sec-0024"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/full#CD003992-sec-0025"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/full#CD003992-sec-0047"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/full#CD003992-sec-0067"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/appendices#CD003992-sec-0073"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/table_n/CD003992StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/table_n/CD003992StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/information#CD003992-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Liat Vidal</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/information#CD003992-cr-0003">Itsik Ben dor</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/information#CD003992-cr-0004">Mical Paul</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/information#CD003992-cr-0005">Noa Eliakim‐Raz</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/information#CD003992-cr-0006">Ellisheva Pokroy</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/information#CD003992-cr-0007">Karla Soares‐Weiser</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003992.pub3/information#CD003992-cr-0008">Leonard Leibovici</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/information/en#CD003992-sec-0081">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 October 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003992.pub3">https://doi.org/10.1002/14651858.CD003992.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003992-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003992-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003992-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003992-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003992-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003992-abs-0001" lang="en"> <section id="CD003992-sec-0001"> <h3 class="title" id="CD003992-sec-0001">Background</h3> <p>Fever occurring in a neutropenic patient remains a common life‐threatening complication of cancer chemotherapy. The common practice is to admit the patient to hospital and treat him or her empirically with intravenous broad‐spectrum antibiotics. Oral therapy could be an alternative approach for selected patients. </p> </section> <section id="CD003992-sec-0002"> <h3 class="title" id="CD003992-sec-0002">Objectives</h3> <p>To compare the efficacy of oral antibiotics versus intravenous (IV) antibiotic therapy in febrile neutropenic cancer patients. </p> </section> <section id="CD003992-sec-0003"> <h3 class="title" id="CD003992-sec-0003">Search methods</h3> <p>The Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 1) in The Cochrane Library, MEDLINE (1966 to January week 4, 2013), EMBASE (1980 to 2013 week 4) and LILACS (1982 to 2007). We searched several databases for ongoing trials. We checked the conference proceedings of the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) (1995 to 2007), and all references of included studies and major reviews were scanned. </p> </section> <section id="CD003992-sec-0004"> <h3 class="title" id="CD003992-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) comparing oral antibiotic(s) to intravenous antibiotic(s) for the treatment of neutropenic cancer patients with fever. The comparison between the two could be started initially (initial oral) or following an initial course of intravenous antibiotic treatment (sequential). </p> </section> <section id="CD003992-sec-0005"> <h3 class="title" id="CD003992-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trial eligibility and methodological quality and extracted data. Data concerning mortality, treatment failures and adverse events were extracted from the included studies assuming an 'intention‐to‐treat' basis for the outcome measures whenever possible. Risk ratios (RR) with 95% confidence intervals (CI) were estimated for dichotomous data. Risk of bias assessment was also made in line with methodology of The Cochrane Collaboration. </p> </section> <section id="CD003992-sec-0006"> <h3 class="title" id="CD003992-sec-0006">Main results</h3> <p>Twenty‐two trials (3142 episodes in 2372 patients) were included in the analyses. The mortality rate was similar when comparing oral to intravenous antibiotic treatment (RR 0.95, 95% CI 0.54 to 1.68, 9 trials, 1392 patients, median mortality 0, range 0% to 8.8%). Treatment failure rates were also similar (RR 0.96, 95% CI 0.86 to 1.06, all trials). No significant heterogeneity was shown for all comparisons but adverse events. The effect was stable in a wide range of patients. Quinolones alone or combined with another antibiotic were used with comparable results. Adverse reactions, mostly gastrointestinal, were more common with oral antibiotics. </p> </section> <section id="CD003992-sec-0007"> <h3 class="title" id="CD003992-sec-0007">Authors' conclusions</h3> <p>Based on the present data, oral treatment is an acceptable alternative to intravenous antibiotic treatment in febrile neutropenic cancer patients (excluding patients with acute leukaemia) who are haemodynamically stable, without organ failure, and do not have pneumonia, infection of a central line or a severe soft‐tissue infection. The wide CI for mortality allows the present use of oral treatment in groups of patients with an expected low risk for mortality, and further research should be aimed at clarifying the definition of low risk patients. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003992-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003992-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003992-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003992-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003992-abs-0004">Français</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003992-abs-0003" lang="en"> <h3>Oral antibiotics for treating febrile neutropenia in cancer patients at low risk for complications </h3> <p>Neutropenia (low white blood cell count) is a complication of cancer chemotherapy that exposes patients to life‐threatening infections. Current practice for neutropenic patients with fever is hospital admission and treatment with intravenous antibiotics. Febrile neutropenia encompasses a spectrum of disease severity and low risk patients may be treated less aggressively. This review of randomised controlled trials showed comparable death and failure rates for oral and intravenous antibiotics for low risk patients, those with solid tumours or chronic leukaemia or lymphoma, and independent of age, source of infection and severity of the neutropenia. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003992-sec-0068" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003992-sec-0068"></div> <h3 class="title" id="CD003992-sec-0069">Implications for practice</h3> <section id="CD003992-sec-0069"> <p>Oral antibiotic therapy can be safely offered to febrile children and adults with neutropenia who are haemodynamically stable, have no organ failure, can take oral medications, do not have pneumonia, infection of a central line or a severe soft‐tissue infection, and do not suffer from acute leukaemia. These criteria stand in close proximity to those of the IDSA guidelines for the treatment of neutropenic patients (<a href="./references#CD003992-bbs2-0089" title="HughesWT , ArmstrongD , BodeyGP , BowEJ , BrownAE , CalandraT , et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectious Diseases2002;34(6):730‐51. ">Hughes 2002</a>). Selection of candidates for oral therapy can also be based on the MASCC scoring system (<a href="./references#CD003992-bbs2-0093" title="KlasterskyJ , PaesmansM , RubensteinEB , BoyerM , EltingL , FeldR , et al. The multinational association for supportive care in cancer risk index: A multinational scoring system for identifying low‐risk febrile neutropenic cancer patients. Journal of Clinical Oncology2000;18(16):3038‐51. ">Klastersky 2000</a>). </p> <p>The analysis offered no data in support of a specific oral regimen, but in light of the preponderance of Gram‐positive infections (<a href="./references#CD003992-bbs2-0083" title="EORTC International Antimicrobial Therapy Cooperative Group. Gram‐positive bacteraemia in granulocytopenic cancer patients. European Journal of Cancer1990;26(5):569‐74. ">EORTC 1990</a>; <a href="./references#CD003992-bbs2-0089" title="HughesWT , ArmstrongD , BodeyGP , BowEJ , BrownAE , CalandraT , et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectious Diseases2002;34(6):730‐51. ">Hughes 2002</a>; <a href="./references#CD003992-bbs2-0045" title="KamanaM , EscalanteC , MullenCA , Frisbee‐HumeS , RolstonKV . Bacterial infections in low‐risk, febrile neutropenic patients. Cancer2005;104(2):422‐6. ">Kamana 2005</a>) the combination of a quinolone and a second drug active against Gram‐positive bacteria (for example ampicilin‐clavulanate) seems prudent. </p> <p>This review did not refer to the issue of home therapy. It could be assumed that home therapy can be offered to a similar population as that approved for oral treatment. In some of the included studies oral therapy was given on an ambulatory basis. The view is that patients can be treated in hospital or under close supervision on an ambulatory basis. </p> </section> <h3 class="title" id="CD003992-sec-0070">Implications for research</h3> <section id="CD003992-sec-0070"> <p>A future trial of oral versus intravenous antibiotic treatment should include febrile neutropenic patients with mild and stable sepsis, regardless of their underlying disorder, source of infection or neutrophil count. Its sample size should be based on considerations of equivalence (<a href="./references#CD003992-bbs2-0090" title="JonesB , JarvisP , LewisJA , EbbuttAF . Trials to assess equivalence: the importance of rigorous methods. BMJ1996;313(7048):36‐9. ">Jones 1996</a>). The definitions of response and failure and the reported outcomes should be based on the guidelines on methodology for clinical trials involving patients with fever and neutropenia (<a href="./references#CD003992-bbs2-0084" title="FeldR . Criteria for response in patients in clinical trials of empiric antibiotic regimens for febrile neutropenia. Is there agreement?. Supportive Care in Cancer1998;6(5):444‐8. ">Feld 1998</a>; <a href="./references#CD003992-bbs2-0085" title="FeldR . Multinational cooperation in trials and guidelines dealing with febrile neutropenia. International Journal of Antimicrobial Agents2000;16(2):185‐7. ">Feld 2000</a>; <a href="./references#CD003992-bbs2-0086" title="FeldR , PaesmansM , FreifeldAG , KlasterskyJ , PizzoPA , RolstonKV , et al. Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies. Clinical Infectious Diseases2002;35(12):1463‐8. ">Feld 2002</a>). </p> <p>For low risk patients (as defined by MASCC or the above criteria) different oral regimens should be compared. Using mortality as the primary outcome in such a trial might translate into a prohibitive sample size. However, the sample size of a trial needed to further reduce the CI shown in the present analysis might be smaller and manageable. </p> <p>In addition, a randomised controlled trial comparing different oral antibiotic regimens in low risk patients with fever and neutropenia, and in particular fourth generation quinolones with activity against Gram‐positive bacteria and anaerobes versus a previous generation quinolone plus ampicilin‐clavulanate, is warranted. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003992-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003992-sec-0022"></div> <div class="table" id="CD003992-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oral compared to intravenous antibiotic therapy for febrile neutropenia in cancer patients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral compared to intravenous antibiotic therapy for febrile neutropenia in cancer patients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with febrile neutropenia in cancer patients<br/> <b>Settings:</b> <br/> <b>Intervention:</b> oral<br/> <b>Comparison:</b> intravenous antibiotic therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> intravenous antibiotic therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Oral</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.95</b> <br/> (0.54 to 1.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1392<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 1000</b> <br/> (17 to 54) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Low risk</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment failure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.96</b> <br/> (0.86 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3142<br/> (22 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>284 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>272 per 1000</b> <br/> (244 to 301) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>211 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>203 per 1000</b> <br/> (181 to 224) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment failure ‐ per protocol analysis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.98</b> <br/> (0.86 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2912<br/> (22 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>225 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>221 per 1000</b> <br/> (194 to 250) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>184 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>180 per 1000</b> <br/> (158 to 204) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events requiring discontinuation of antibiotics</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.45</b> <br/> (0.61 to 3.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1823<br/> (15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> <br/> (13 to 73) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment failure not dt modification in update</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.95</b> <br/> (0.85 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3041<br/> (21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>267 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>254 per 1000</b> <br/> (227 to 283) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>180 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>171 per 1000</b> <br/> (153 to 191) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> High risk of detection bias in most of the trials </p> <p><sup>2</sup> A wide CI </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003992-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003992-sec-0023"></div> <p>Patients with cancer who experience fever while being neutropenic are at risk of serious infections (<a href="./references#CD003992-bbs2-0081" title="BodeyGP , BuckleyM , SatheYS , FreireichEJ . Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals of Internal Medicine1966;64(2):328‐40. ">Bodey 1966</a>; <a href="./references#CD003992-bbs2-0092" title='KlaassenRJ , GoodmanTR , PhamB , DoyleJJ . "Low‐risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. Journal of Clinical Oncology2000;18(5):1012‐9. '>Klaassen 2000a</a>; <a href="./references#CD003992-bbs2-0094" title="LucasKG , BrownAE , ArmstrongD , ChapmanD , HellerG . The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer1996;77(4):791‐8. ">Lucas 1996</a>; <a href="./references#CD003992-bbs2-0096" title="PizzoPA , RobichaudKJ , WesleyR , CommersJR . Fever in the pediatric and young adult patients with cancer. A prospective study of 1001 episodes. Medicine (Baltimore)1982;61(3):153‐65. ">Pizzo 1982</a>; <a href="./references#CD003992-bbs2-0097" title="RackoffWR , GoninR , RobinsonC , KreissmanSG , BreitfeldPB . Predicting the risk of bacteremia in childen with fever and neutropenia. Journal of Clinical Oncology1996;14(3):919‐24. ">Rackoff 1996</a>). Empirical use of antibiotics, based on previous practice without knowledge of the cause of infection, has lowered the incidence of death and serious complications (<a href="./references#CD003992-bbs2-0099" title="SchimpffS , SatterleeW , YoungVM , SerpickA . Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. The New England Journal of Medicine1971;284(19):1061‐5. ">Schimpff 1971</a>; <a href="./references#CD003992-bbs2-0100" title="SchimpffS . Empiric antibiotic therapy for granulocytopenic cancer patients. The American Journal of Medicine1986;80(5C):13‐20. ">Schimpff 1986</a>, <a href="./references#CD003992-bbs2-0102" title="TalcottJA , FinbergR , MayerRJ , GoldmanL . The medical course of cancer patients with fever and neutropenia. Clinical identification of a low‐risk subgroup at presentation. Archives of Internal Medicine1988;148(12):2561‐8. ">Talcott 1988</a>; <a href="./references#CD003992-bbs2-0105" title="ViscoliC . Management of infection in cancer patients. Studies of the EORTC International Antimicrobial Therapy Group (IATG). European Journal of Cancer2002;38 Suppl 4:S82‐7. ">Viscoli 2002</a>). Traditionally the practice is to admit and treat neutropenic patients empirically with intravenous (IV) broad‐spectrum antibiotics at the emergence of a fever (<a href="./references#CD003992-bbs2-0089" title="HughesWT , ArmstrongD , BodeyGP , BowEJ , BrownAE , CalandraT , et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectious Diseases2002;34(6):730‐51. ">Hughes 2002</a>). </p> <p>The empirical selection of an appropriate antibiotic is based on the patient's immune status (that is being neutropenic) as well as the suspected invading organism and its susceptibility to antibiotics. Neutropenic cancer patients form a heterogeneous group. A retrospective study indicated the existence of a patient subpopulation responding promptly to antibiotic therapy, thus raising the possibility of using different treatment strategies, such as oral therapy and outpatient treatment (<a href="./references#CD003992-bbs2-0102" title="TalcottJA , FinbergR , MayerRJ , GoldmanL . The medical course of cancer patients with fever and neutropenia. Clinical identification of a low‐risk subgroup at presentation. Archives of Internal Medicine1988;148(12):2561‐8. ">Talcott 1988</a>). In parallel, the pattern of pathogens (that is bacteria) in neutropenic patients with fever has changed, with a declining incidence of Gram‐negative bacteraemia and increasing incidence of Gram‐positive infections (<a href="./references#CD003992-bbs2-0083" title="EORTC International Antimicrobial Therapy Cooperative Group. Gram‐positive bacteraemia in granulocytopenic cancer patients. European Journal of Cancer1990;26(5):569‐74. ">EORTC 1990</a>; <a href="./references#CD003992-bbs2-0087" title="HannI , ViscoliC , PaesmansM , GayaH , GlauserM . A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). British Journal of Haematology1997;99(3):580‐8. ">Hann 1997</a>; <a href="./references#CD003992-bbs2-0089" title="HughesWT , ArmstrongD , BodeyGP , BowEJ , BrownAE , CalandraT , et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectious Diseases2002;34(6):730‐51. ">Hughes 2002</a>), resulting in a change in antibiotic practice. Oral treatment became a viable option with the advent of new extended spectrum oral antibiotics. The potential of oral treatment and the deleterious effects of hospitalisation (with need for an intravenous access line, exposure to multi‐drug resistant organisms) and greater awareness of the importance of quality of life and patient satisfaction, especially among cancer patients (<a href="./references#CD003992-bbs2-0104" title="TalcottJA , WhalenA , ClarkJ , RiekerPP , FinbergR . Home antibiotic therapy for low‐risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. Journal of Clinical Oncology1994;12(1):107‐14. ">Talcott 1994</a>), has led to a re‐evaluation of the approach to neutropenic febrile patients. </p> <p>Research has therefore focused on methods to prospectively identify neutropenic patients with fever who are at low risk of complications. Several clinical prediction rules were developed and validated for children and adult populations at low risk (<a href="./references#CD003992-bbs2-0092" title='KlaassenRJ , GoodmanTR , PhamB , DoyleJJ . "Low‐risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. Journal of Clinical Oncology2000;18(5):1012‐9. '>Klaassen 2000a</a>; <a href="./references#CD003992-bbs2-0093" title="KlasterskyJ , PaesmansM , RubensteinEB , BoyerM , EltingL , FeldR , et al. The multinational association for supportive care in cancer risk index: A multinational scoring system for identifying low‐risk febrile neutropenic cancer patients. Journal of Clinical Oncology2000;18(16):3038‐51. ">Klastersky 2000</a>; <a href="./references#CD003992-bbs2-0097" title="RackoffWR , GoninR , RobinsonC , KreissmanSG , BreitfeldPB . Predicting the risk of bacteremia in childen with fever and neutropenia. Journal of Clinical Oncology1996;14(3):919‐24. ">Rackoff 1996</a>; <a href="./references#CD003992-bbs2-0102" title="TalcottJA , FinbergR , MayerRJ , GoldmanL . The medical course of cancer patients with fever and neutropenia. Clinical identification of a low‐risk subgroup at presentation. Archives of Internal Medicine1988;148(12):2561‐8. ">Talcott 1988</a>; <a href="./references#CD003992-bbs2-0103" title="TalcottJA , SiegelRD , FinbergR , GoldmanL . Risk assessment in cancer patients with fever and neutropenia: a prospective, two‐center validation of a prediction rule. Journal of Clinical Oncology1992;10(2):316‐22. ">Talcott 1992</a>). Talcott et al constructed four groups out of which one included patients with an expected low complications rate. The patients at low risk developed fever out of hospital, had controlled cancer and had no co‐morbidity. The rule was validated prospectively and later tested in a pilot study for its ability to select patients for early switch from IV to oral treatment (<a href="./references#CD003992-bbs2-0103" title="TalcottJA , SiegelRD , FinbergR , GoldmanL . Risk assessment in cancer patients with fever and neutropenia: a prospective, two‐center validation of a prediction rule. Journal of Clinical Oncology1992;10(2):316‐22. ">Talcott 1992</a>). A consensus panel, the Multinational Association for Supportive Care in Cancer (MASCC), developed a set of criteria that are predictors of good prognosis in 'low risk' adult patients: acquisition of fever out of hospital, age younger then 60 years, absent to moderate symptoms, no hypotension, no chronic bronchitis, and a background of either a solid tumour or haematological malignancy with no history of fungal infection; in a validated scoring system. While receiving conventional therapy patients with a score of equal to or greater than 21 had a low rate of serious medical complication (6%) and only 1% mortality (<a href="./references#CD003992-bbs2-0093" title="KlasterskyJ , PaesmansM , RubensteinEB , BoyerM , EltingL , FeldR , et al. The multinational association for supportive care in cancer risk index: A multinational scoring system for identifying low‐risk febrile neutropenic cancer patients. Journal of Clinical Oncology2000;18(16):3038‐51. ">Klastersky 2000</a>). </p> <p>Simultaneously, clinical trials (<a href="./references#CD003992-bbs2-0011" title="MalikIA , AbbasZ , KarimM . Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet1992;339:1092‐6. ">Malik 1992</a>; <a href="./references#CD003992-bbs2-0018" title="RubensteinEB , RolstonK , BenjaminRS , LoewyJ , EscalanteC , ManzulloE , et al. Outpatient treatment of febrile episodes in low‐risk neutropenic patients with cancer. Cancer1993;71:3640‐6. ">Rubenstein 1993</a>) have examined the safety and feasibility of oral antibiotic treatment in selected patients. In the absence of an accepted definition there was no consistency in the selection of patients defined as a 'low risk' group. Most of these trials were small, single centre trials. Thus, although reporting similar rates of success for oral and intravenous therapy, the superiority of an intravenous regimen cannot be ruled out. </p> <p>The most recent guidelines for antibiotic treatment in neutropenic patients with cancer (<a href="./references#CD003992-bbs2-0089" title="HughesWT , ArmstrongD , BodeyGP , BowEJ , BrownAE , CalandraT , et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectious Diseases2002;34(6):730‐51. ">Hughes 2002</a>) are very cautious regarding the use of oral antibiotics alone. They recommend careful selection of low risk patients and limit this approach to adults, of whom only some may receive the treatment at home. </p> <p>In the present systematic review we intended to provide better evidence regarding the safety and efficacy of oral treatment as opposed to intravenous treatment. We tried to clarify the definitions of the low risk subgroup and the appropriate antibiotics for oral treatment as well as the limits of present knowledge. </p> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003992-sec-0024" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003992-sec-0024"></div> <p>To compare the efficacy of oral antibiotics versus intravenous antibiotic therapy in febrile neutropenic cancer patients. </p> <p>In addition, we compared the efficacy of these treatment modalities in the following subgroups. </p> <p> <ul id="CD003992-list-0001"> <li> <p>Patients with unexplained fever (versus documented infection).</p> </li> <li> <p>Patients with an absolute neutrophil count of more than 0.1 cells x 10^9/L (versus those with a lower neutrophil count). </p> </li> <li> <p>Patients with a solid tumour (versus those with a haematological malignancy).</p> </li> <li> <p>Patients 60 years old and under (versus those above 60 years).</p> </li> <li> <p>Children (according to trial definition) (versus adults).</p> </li> </ul> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003992-sec-0025" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003992-sec-0025"></div> <section id="CD003992-sec-0026"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003992-sec-0027"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) comparing any oral antibiotics to any intravenous (IV) antibiotics for the treatment of febrile neutropenia in cancer patients. The oral antibiotics could be started at presentation in patients allocated to oral treatment (viz, initial oral) or as part of a sequential IV to oral strategy where all patients were initially treated intravenously and those allocated to oral treatment were switched to oral therapy after a predefined time independent of the neutropenic episode (viz., sequential). </p> </section> <section id="CD003992-sec-0028"> <h4 class="title">Types of participants</h4> <p>Patients with cancer and chemotherapy‐induced neutropenia or patients with cancer who underwent bone marrow transplantation who presented with fever. </p> </section> <section id="CD003992-sec-0029"> <h4 class="title">Types of interventions</h4> <p>A comparison of the following.</p> <p>(1) Any oral antibiotics, administered as a single drug or as a combination of orally administered antibiotics.<br/> (2) Any antibiotics administered intravenously, either as monotherapy or combination therapy. </p> <p>Studies in which patients were allocated to these regimens initially, before administration of any other antibiotics for the specific febrile episode (initial oral), were analysed separately from studies in which intravenous antibiotics had been first given to all patients (that is sequential intravenous to oral therapy). </p> </section> <section id="CD003992-sec-0030"> <h4 class="title">Types of outcome measures</h4> <section id="CD003992-sec-0031"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD003992-list-0002"> <li> <p>All cause mortality at 30 days follow‐up</p> </li> <li> <p>Mortality caused by the infectious episode at end of follow‐up (restricted to 30 days)</p> </li> <li> <p>Treatment failure (restricted to 30 days)</p> </li> </ul> </p> <p>For the purpose of this review, treatment failure was defined as a composite endpoint comprising one or more of the following: death; persistence, recurrence or worsening of clinical signs or symptoms of presenting infection; any addition to or modification of the assigned intervention (<a href="./references#CD003992-bbs2-0082" title="From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. Journal of Infectious Diseases1990;161(3):397‐401. ">Consensus panel 1990</a>; <a href="./references#CD003992-bbs2-0084" title="FeldR . Criteria for response in patients in clinical trials of empiric antibiotic regimens for febrile neutropenia. Is there agreement?. Supportive Care in Cancer1998;6(5):444‐8. ">Feld 1998</a>). </p> </section> <section id="CD003992-sec-0032"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD003992-list-0003"> <li> <p>Treatment failure not due to modification of the primary intervention</p> </li> <li> <p>Lost to follow‐up before end of study (dropouts)</p> </li> </ul> </p> <section id="CD003992-sec-0033"> <h6 class="title">Adverse effects</h6> <p> <ul id="CD003992-list-0004"> <li> <p>Life‐threatening or associated with permanent disability</p> </li> <li> <p>Requiring discontinuation of therapy</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD003992-sec-0034"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003992-sec-0035"> <h4 class="title">Electronic searches</h4> <p>Relevant trials were identified by searching the Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 1) (<a href="./appendices#CD003992-sec-0074">Appendix 1</a>), MEDLINE (1966 to January week 4, 2013) (<a href="./appendices#CD003992-sec-0075">Appendix 2</a>), EMBASE (1980 to 2013 week 4) (<a href="./appendices#CD003992-sec-0076">Appendix 3</a>) and LILACS (1982 to 2007) (<a href="./appendices#CD003992-sec-0077">Appendix 4</a>). </p> </section> <section id="CD003992-sec-0036"> <h4 class="title">Searching other resources</h4> <p>References of all identified studies as well as major reviews were inspected for more studies. We searched the following conference proceedings for unpublished trials: Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (1995 to 2006); The American Society of Hematology (2001 to 2002) (available at http://www.hematology.org/). We searched the following trial databases for ongoing and unpublished trials: Current Controlled Trials in the metaRegister of controlled clinical trials (http://www.controlled‐trials.com/); UKCCCR Register of Cancer Trials (www.ctu.mrc.ac.uk/ukcccr); PDQ (Physician Data Query) database of the National Cancer Institute (http://www.cancer.gov/search/clinical_trials/); and the National Institutes of Health database (http://clinicaltrials‐nccs.nlm.nih.gov/). </p> <p>Additionally, the first or corresponding author of each included study and pharmaceutical companies were contacted for complementary information or information regarding unpublished trials. Letters, abstracts and unpublished trials were accepted in order to reduce the influence of publication bias. </p> </section> </section> <section id="CD003992-sec-0037"> <h3 class="title" id="CD003992-sec-0037">Data collection and analysis</h3> <section id="CD003992-sec-0038"> <h4 class="title">Selection of studies</h4> <p>One review author inspected the abstract of each reference identified by the search and applied the inclusion criteria. For possibly relevant articles the full article was obtained and inspected by two review authors independently. </p> </section> <section id="CD003992-sec-0039"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted data from the included trials. In addition the third review author extracted data from 10% of the studies, selected randomly. Data extractions were discussed, decisions documented, and all authors of included studies were contacted for clarification. Justifications for excluding studies from the review were also documented. Differences in the data extracted were resolved by discussion. In the case of disagreement between the two review authors, a third review author extracted the data. All data were collected on an intention‐to‐treat (ITT) basis whenever possible. </p> <p>Trials were identified by the name of the first author and year in which the trial was first published, and ordered chronologically. The following data were extracted, checked and recorded. </p> <section id="CD003992-sec-0040"> <h5 class="title">Characteristics of trials</h5> <p> <ul id="CD003992-list-0005"> <li> <p>Date, location and setting of trial (inpatients or ambulatory patients)</p> </li> <li> <p>Publication status</p> </li> <li> <p>Case definitions used (inclusion and exclusion criteria)</p> </li> <li> <p>Design (intention to treat, method of randomisation and allocation)</p> </li> <li> <p>Unit of randomisation</p> </li> <li> <p>Sponsor of trial</p> </li> </ul> </p> </section> <section id="CD003992-sec-0041"> <h5 class="title">Characteristics of patients</h5> <p> <ul id="CD003992-list-0006"> <li> <p>Number of participants and number of episodes in each group</p> </li> <li> <p>Age (mean and SD, or median plus range)</p> </li> <li> <p>Underlying malignancy and malignancy status</p> </li> <li> <p>Site of infection (three most common)</p> </li> <li> <p>Disease severity measure: septic shock, confusion, respiratory, liver and renal impairment</p> </li> <li> <p>Percentage of patients with neutrophil count more than 0.1 cells x 10^9/L in each group </p> </li> <li> <p>Percentage of patients with a solid tumour or lymphoma and chronic leukaemia in each group </p> </li> <li> <p>Number of patients with unexplained fever in each group</p> </li> <li> <p>The three most common pathogens (Gram‐negative bacteria, Gram‐positive bacteria)</p> </li> <li> <p>Number of patients developing resistant superinfection or colonisation, or both</p> </li> <li> <p>Number of patients 60 years of age and younger</p> </li> <li> <p>Number of children (according to trial's definition)</p> </li> </ul> </p> </section> <section id="CD003992-sec-0042"> <h5 class="title">Characteristics of interventions</h5> <p> <ul id="CD003992-list-0007"> <li> <p>Antibiotic type, mode of administration, dose and interval</p> </li> <li> <p>'Initially oral' or 'sequential intravenous to oral' study (see: 'Types of studies')</p> </li> <li> <p>Duration of therapy (median)</p> </li> </ul> </p> </section> <section id="CD003992-sec-0043"> <h5 class="title">Characteristics of outcome measures</h5> <p> <ul id="CD003992-list-0008"> <li> <p>Number of deaths at 30 days or during the study duration</p> </li> <li> <p>Mortality caused by the infectious episode</p> </li> <li> <p>Number of treatment failures (as defined)</p> </li> <li> <p>Number of treatment failures not due to addition of intravenous antibiotic for the primary infection </p> </li> <li> <p>Adverse reactions (causing death or permanent disability; requiring discontinuation; any other) </p> </li> <li> <p>Number of patients excluded after randomisation</p> </li> <li> <p>Lost to follow‐up (dropouts) before the end of study</p> </li> </ul> </p> </section> </section> <section id="CD003992-sec-0044"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors working independently assessed the trials fulfilling the review inclusion criteria for methodological quality. This was done using the criteria described in the Cochrane Handbook for Systematic Reviews of Interventions (<a href="./references#CD003992-bbs2-0088" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. Oxford: Update Software, updated quarterly. ">Higgins 2011</a>), which are based on the evidence of a strong association between poor allocation concealment and overestimation of effect (<a href="./references#CD003992-bbs2-0101" title="SchulzKF , ChalmersI , HayesRJ , AltmanD . Empirical evidence of bias. JAMA1995;273(5):408‐12. ">Schulz 1995</a>), as defined below.<br/> A. Low risk of bias (adequate allocation concealment).<br/> B. Moderate risk of bias (uncertainty regarding allocation concealment).<br/> C. High risk of bias (inadequate allocation concealment).<br/> In addition to the adequacy of allocation concealment, methods of allocation generation, blinding, intention‐to‐treat analysis, exclusions after randomisation, randomisation unit and publication status were recorded independently by the two review authors. Measures of quality were used for sensitivity analysis. </p> </section> <section id="CD003992-sec-0045"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity (degree of difference between the results of different trials) in the results of the trials was initially graphically inspected and assessed by a test of heterogeneity (Chi<sup>2</sup> test and I<sup>2</sup> statistic). We had anticipated between‐trial variation in estimation of morbidity and mortality for studies comparing broad‐spectrum oral treatment versus narrow‐spectrum treatment and for studies comparing patients at different risk levels. Heterogeneity was explored through stratifying the above defined patient subgroups (in the 'Objectives'), separating patients with low risk criteria (<a href="#CD003992-tbl-0002">Table 1</a>). </p> <div class="table" id="CD003992-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Criteria for low risk patients (as defined in most included studies)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Common criteria</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haemodynamic stablity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No organ failure</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ability to take oral medications</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No pneumonia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No infection of a central line</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No severe soft‐tissue infection</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No acute leukaemia as the background malignancy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No known drug allergy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not pregnant or lactating women</p> </td> </tr> </tbody> </table> </div> <p>A funnel plot estimating the treatment effect against the precision of the trials (plots of the log of the relative risk for efficacy against the standard error) was examined in order to estimate potential asymmetry that may indicate selection bias (the selective publication of trials with positive findings) or methodological flaw in the small studies. </p> </section> <section id="CD003992-sec-0046"> <h4 class="title">Data synthesis</h4> <p>Pooled risk ratios (RR) with 95% confidence intervals (CIs) were calculated for dichotomous data. Exclusions after randomisation were reported. A fixed‐effect model (Mantel‐Haenszel method) was used unless significant heterogeneity (P less than 0.10) was detected, in which case a random‐effects model (DerSimonian and Laird method) was used. </p> <p>Subgroup analyses were performed to investigate the effects of age (children versus adults), source of infection (unexplained fever versus documented infection), severity of neutropenia (absolute neutrophil count equal to or greater than 0.1 cells x 10^9/L versus absolute neutrophil count less than 0.1 cells x 10^9/L), and type of malignancy (solid tumour versus haematological malignancy). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003992-sec-0047" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003992-sec-0047"></div> <section id="CD003992-sec-0048"> <h3 class="title">Description of studies</h3> <section id="CD003992-sec-0049"> <h4 class="title">Results of the search</h4> <p>Potentially relevant references were identified through the electronic databases. These references were screened for RCTs in cancer patients with neutropenia, fever and antibiotic regimens according to the protocol. Eighty trials were considered potentially eligible for this review, including six articles identified through references cited in the included studies and in major review articles in the field (<a href="./references#CD003992-bbs2-0037" title="FreifeldA , PizzoP . Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients. The Pediatric Infectious Disease Journal1997;16:140‐5; discussion 145‐6, 160‐2. ">Freifeld 1997</a>; <a href="./references#CD003992-bbs2-0089" title="HughesWT , ArmstrongD , BodeyGP , BowEJ , BrownAE , CalandraT , et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectious Diseases2002;34(6):730‐51. ">Hughes 2002</a>; <a href="./references#CD003992-bbs2-0091" title="KernWV . Risk assessment and risk‐based therapeutic strategies in febrile neutropenia. Current Opinion in Infectious Diseases2001;14(4):415‐22. ">Kern 2001a</a>; <a href="./references#CD003992-bbs2-0092" title='KlaassenRJ , GoodmanTR , PhamB , DoyleJJ . "Low‐risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. Journal of Clinical Oncology2000;18(5):1012‐9. '>Klaassen 2000a</a>; <a href="./references#CD003992-bbs2-0095" title="PaesmansM . Risk factors assessment in febrile neutropenia. International Journal of Antimicrobial Agents2000;16(2):107‐11. ">Paesmans 2000</a>; <a href="./references#CD003992-bbs2-0098" title="RolstonKV . New trends in patient management: risk‐based therapy for febrile patients with neutropenia. Clinical infectious diseases1999;29(3):515‐21. ">Rolston 1999</a>; <a href="./references#CD003992-bbs2-0105" title="ViscoliC . Management of infection in cancer patients. Studies of the EORTC International Antimicrobial Therapy Group (IATG). European Journal of Cancer2002;38 Suppl 4:S82‐7. ">Viscoli 2002</a>). </p> </section> <section id="CD003992-sec-0050"> <h4 class="title">Included studies</h4> <p>Twenty‐two published RCTs were included in the review. Additionally two conference proceedings, identified through the ICAAC search, were included (<a href="./references#CD003992-bbs2-0017" title="RolstonK , RubensteinE , EltingL , EscalanteC , ManzulloE , BodeyGP . Ambulatory management of febrile episodes in low‐risk neutropenic patients. Interscience conference on antimicrobial agents and chemotherapy. 1995:LM81. ">Rolston 1995</a>; <a href="./references#CD003992-bbs2-0019" title="AnaissieEJ , SamonisG , KalbakisK , GeorgouliasV . Therapy for low‐risk cancer patients with fever and neutropenia: results of a prospective, randomized trial with cost analysis. Interscience conference on antimicrobial agents and chemotherapy. 1997:LM‐51. ">Samonis 1997</a>). Further information was provided by Dr Anaissie (<a href="./references#CD003992-bbs2-0019" title="AnaissieEJ , SamonisG , KalbakisK , GeorgouliasV . Therapy for low‐risk cancer patients with fever and neutropenia: results of a prospective, randomized trial with cost analysis. Interscience conference on antimicrobial agents and chemotherapy. 1997:LM‐51. ">Samonis 1997</a>). </p> <p>The studies were performed between the years 1989 and 2007, and included 965 randomised patients and an additional 2177 randomised episodes in 1407 patients. The age of the patients ranged from nine months to 85 years. Oral antibiotics were compared to intravenous antibiotics, both given empirically and as the initial empirical treatment ('initial oral') in 16 trials (<a href="./references#CD003992-bbs2-0001" title="BrackE , BodmerN , SimonA , LeibundgutK , KühneT , NiggliFK , et al. First‐day step‐down to oral outpatient treatment versus continued standard treatment in children with cancer and low‐risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study. Pediatric Blood &amp; Cancer2012;59(3):423‐30. LüthiF , LeibundgutK , NiggliFK , NadalD , AebiC , BodmerN , et al. Serious medical complications in children with cancer and fever in chemotherapy‐induced neutropenia: results of the prospective multicenter SPOG 2003 FN study. Pediatric Blood &amp; Cancer2012;59(1):90‐5. ">Brack 2012*</a>; <a href="./references#CD003992-bbs2-0002" title="CagolAR , Castro JuniorCG , MartinsMC , MachadoAL , RibeiroRC , GregianinLJ , et al. Oral vs. intravenous empirical antimicrobial therapy in febrile neutropenic patients receiving childhood cancer chemotherapy. Jornal de Pediatria2009;85(6):531‐5. ">Cagol 2009*</a>; <a href="./references#CD003992-bbs2-0003" title="CornelyOA , WickeT , SeifertH , BetheU , SchwonzenM , ReichertD , et al. Once‐daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. International Journal of Hematology2004;79(1):74‐8. [MEDLINE: 14979482] ">Cornely 2003</a>; <a href="./references#CD003992-bbs2-0005" title="FreifeldA , MarchigianiD , WalshT , ChanockS , LewisL , HiemenzJ , et al. A double‐blind comparison of empirical oral and intravenous antibiotic therapy for low‐risk febrile patients with neutropenia during cancer chemotherapy. The New England Journal of Medicine1999;341(5):305‐11. ">Freifeld 1999</a>; <a href="./references#CD003992-bbs2-0007" title="GuptaA , SwaroopC , AgarwalaS , PandeyRM , BakhshiS . Randomized controlled trial comparing oral amoxicillin‐clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low‐risk febrile neutropenia. Journal of Pediatric Hematology/Oncology2009;31(9):635‐41. ">Gupta 2009*</a>; <a href="./references#CD003992-bbs2-0008" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer1999;85:213‐9. ">Hidalgo 1999</a>; <a href="./references#CD003992-bbs2-0009" title="InnesHE , SmithDB , O'ReillySM , ClarkPI , KellyV , MarshallE . Oral antibiotics with early hospital discharge compared with inpatient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Data on file. ">Innes 2003</a>; <a href="./references#CD003992-bbs2-0010" title="KernWV , ComettaA , DeBockR , LangenaekenJ , PaesmansM , GayaH . Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. The New England Journal of Medicine1999;341:312‐8. ">Kern 1999</a>; <a href="./references#CD003992-bbs2-0011" title="MalikIA , AbbasZ , KarimM . Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet1992;339:1092‐6. ">Malik 1992</a>; <a href="./references#CD003992-bbs2-0013" title="NihoS , OheY , GotoK , HOhmatsu , TMatsumoto , KKubota , et al. Randomized trial of oral versus intravenous antibiotics in low‐risk febrile neutropenic patients with lung cancer. Japanese Journal of Clinical Oncology2004;34(2):69‐73. [MEDLINE: 15067098] ">Niho 2004</a>; <a href="./references#CD003992-bbs2-0016" title="PetrilliAS , DantasLS , CamposMC , TanakaC , GinaniVC , SeberA . Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low‐risk pediatric oncology patients: randomized prospective trial. Medical and Pediatric Oncology2000;34:87‐91. ">Petrilli 2000</a>; <a href="./references#CD003992-bbs2-0017" title="RolstonK , RubensteinE , EltingL , EscalanteC , ManzulloE , BodeyGP . Ambulatory management of febrile episodes in low‐risk neutropenic patients. Interscience conference on antimicrobial agents and chemotherapy. 1995:LM81. ">Rolston 1995</a>; <a href="./references#CD003992-bbs2-0018" title="RubensteinEB , RolstonK , BenjaminRS , LoewyJ , EscalanteC , ManzulloE , et al. Outpatient treatment of febrile episodes in low‐risk neutropenic patients with cancer. Cancer1993;71:3640‐6. ">Rubenstein 1993</a>; <a href="./references#CD003992-bbs2-0019" title="AnaissieEJ , SamonisG , KalbakisK , GeorgouliasV . Therapy for low‐risk cancer patients with fever and neutropenia: results of a prospective, randomized trial with cost analysis. Interscience conference on antimicrobial agents and chemotherapy. 1997:LM‐51. ">Samonis 1997</a>; <a href="./references#CD003992-bbs2-0020" title="SebbanC , DussartS , FuhrmannC , GhesquieresH , RodriguesI , GeoffroisL , et al. Oral moxifloxacin or intravenous ceftriaxone for the treatment of low‐risk neutropenic fever in cancer patients suitable for early hospital discharge. Supportive Care in Cancer2008;16(9):1017‐23. ">Sebban 2009*</a>; <a href="./references#CD003992-bbs2-0022" title="VelascoE , CostaMA , MartinsCA , NucciM . Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients. American Journal of Clinical Oncology‐Cancer Clinical Trials1995;18(5):429‐35. ">Velasco 1995</a>). In the other five trials (<a href="./references#CD003992-bbs2-0004" title="FlahertyJP , WaitleyD , EdlinB , GeorgeD , ArnowP , O'KeefeP , et al. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. The American Journal of Medicine1989;87 Suppl:278‐82. ">Flaherty 1989</a>; <a href="./references#CD003992-bbs2-0006" title="GiamarellouH , BassarisHP , PetrikkosG , BuschW , VoulgarelisM , AntoniadouA , et al. Monotherapy with intravenous followed by oral high‐dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrobial Agents and Chemotherapy2000;44:3264‐71. ">Giamarellou 2000</a>; <a href="./references#CD003992-bbs2-0012" title="MullenCA , PetropoulosD , RobertsWM , RyttingM , ZipfT , ChanKW , et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer1999;86:126‐34. MullenCA , PetropoulosD , RobertsWM , et al. Economic and resource utilization analysis of outpatient management of fever and neutropenia in low‐risk pediatric patients with cancer. Journal of Pediatric Hematology/Oncology1999;21:212‐8. ">Mullen 1999</a>; <a href="./references#CD003992-bbs2-0014" title="PaganiniHR , SarkisCM , DeMartinoMG , ZubizarretaPA , CasimirL , FernandezC , et al. Oral administration of cefixime to lower risk febrile neutropenic children with cancer. Cancer2000;88:2848‐52. ">Paganini 2000</a>; <a href="./references#CD003992-bbs2-0015" title="PaganiniH , GomezS , RuvinskyS , ZubizarretaP , LatellaA , FraquelliL , et al. Outpatient, sequential, parenteral‐oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single‐center, randomized, controlled trial in Argentina. Cancer2003;97(7):1775–80. [MEDLINE: 12655535] ">Paganini 2003</a>; <a href="./references#CD003992-bbs2-0021" title="ShenepJL , FlynnPM , BakerDK , HetheringtonSV , HudsonMM , HughesWT , et al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clinical Infectious Disease2001;32:36‐43. ">Shenep 2001</a>) the patients randomised to 'oral treatment' received intravenous antibiotics prior to oral therapy ('sequential'). In two sequential trials (<a href="./references#CD003992-bbs2-0004" title="FlahertyJP , WaitleyD , EdlinB , GeorgeD , ArnowP , O'KeefeP , et al. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. The American Journal of Medicine1989;87 Suppl:278‐82. ">Flaherty 1989</a>; <a href="./references#CD003992-bbs2-0006" title="GiamarellouH , BassarisHP , PetrikkosG , BuschW , VoulgarelisM , AntoniadouA , et al. Monotherapy with intravenous followed by oral high‐dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrobial Agents and Chemotherapy2000;44:3264‐71. ">Giamarellou 2000</a>) the randomisation procedure was carried out at presentation but the patients were switched to oral therapy only 72 hours later. </p> <p>Some exclusion criteria were similar among trials: haemodynamic instability, hypotension, altered mental status, respiratory failure, poor clinical condition, renal failure, abnormal liver function tests, no ability to swallow or take oral medication, allergy to study drugs, pregnancy and lactation. Additional case definitions varied between the trials despite the attempts of all trials to identify patients at low risk for mortality and complications (<a href="#CD003992-tbl-0003">Table 2</a>). Patients with haematological malignancy were excluded in three studies (<a href="./references#CD003992-bbs2-0008" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer1999;85:213‐9. ">Hidalgo 1999</a>; <a href="./references#CD003992-bbs2-0013" title="NihoS , OheY , GotoK , HOhmatsu , TMatsumoto , KKubota , et al. Randomized trial of oral versus intravenous antibiotics in low‐risk febrile neutropenic patients with lung cancer. Japanese Journal of Clinical Oncology2004;34(2):69‐73. [MEDLINE: 15067098] ">Niho 2004</a>; <a href="./references#CD003992-bbs2-0019" title="AnaissieEJ , SamonisG , KalbakisK , GeorgouliasV . Therapy for low‐risk cancer patients with fever and neutropenia: results of a prospective, randomized trial with cost analysis. Interscience conference on antimicrobial agents and chemotherapy. 1997:LM‐51. ">Samonis 1997</a>). Patients with acute leukaemia were included in <a href="./references#CD003992-bbs2-0001" title="BrackE , BodmerN , SimonA , LeibundgutK , KühneT , NiggliFK , et al. First‐day step‐down to oral outpatient treatment versus continued standard treatment in children with cancer and low‐risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study. Pediatric Blood &amp; Cancer2012;59(3):423‐30. LüthiF , LeibundgutK , NiggliFK , NadalD , AebiC , BodmerN , et al. Serious medical complications in children with cancer and fever in chemotherapy‐induced neutropenia: results of the prospective multicenter SPOG 2003 FN study. Pediatric Blood &amp; Cancer2012;59(1):90‐5. ">Brack 2012*</a> (after maintenance treatment only); <a href="./references#CD003992-bbs2-0005" title="FreifeldA , MarchigianiD , WalshT , ChanockS , LewisL , HiemenzJ , et al. A double‐blind comparison of empirical oral and intravenous antibiotic therapy for low‐risk febrile patients with neutropenia during cancer chemotherapy. The New England Journal of Medicine1999;341(5):305‐11. ">Freifeld 1999</a> (excluding patients with "neutropenia expected to last greater than 10 days"); <a href="./references#CD003992-bbs2-0007" title="GuptaA , SwaroopC , AgarwalaS , PandeyRM , BakhshiS . Randomized controlled trial comparing oral amoxicillin‐clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low‐risk febrile neutropenia. Journal of Pediatric Hematology/Oncology2009;31(9):635‐41. ">Gupta 2009*</a> (after maintenance treatment only); <a href="./references#CD003992-bbs2-0006" title="GiamarellouH , BassarisHP , PetrikkosG , BuschW , VoulgarelisM , AntoniadouA , et al. Monotherapy with intravenous followed by oral high‐dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrobial Agents and Chemotherapy2000;44:3264‐71. ">Giamarellou 2000</a>; <a href="./references#CD003992-bbs2-0011" title="MalikIA , AbbasZ , KarimM . Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet1992;339:1092‐6. ">Malik 1992</a>; <a href="./references#CD003992-bbs2-0015" title="PaganiniH , GomezS , RuvinskyS , ZubizarretaP , LatellaA , FraquelliL , et al. Outpatient, sequential, parenteral‐oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single‐center, randomized, controlled trial in Argentina. Cancer2003;97(7):1775–80. [MEDLINE: 12655535] ">Paganini 2003</a>; <a href="./references#CD003992-bbs2-0017" title="RolstonK , RubensteinE , EltingL , EscalanteC , ManzulloE , BodeyGP . Ambulatory management of febrile episodes in low‐risk neutropenic patients. Interscience conference on antimicrobial agents and chemotherapy. 1995:LM81. ">Rolston 1995</a>; <a href="./references#CD003992-bbs2-0018" title="RubensteinEB , RolstonK , BenjaminRS , LoewyJ , EscalanteC , ManzulloE , et al. Outpatient treatment of febrile episodes in low‐risk neutropenic patients with cancer. Cancer1993;71:3640‐6. ">Rubenstein 1993</a>. Patients undergoing bone marrow or allogeneic stem cell transplantation were specifically excluded in eight trials (<a href="./references#CD003992-bbs2-0001" title="BrackE , BodmerN , SimonA , LeibundgutK , KühneT , NiggliFK , et al. First‐day step‐down to oral outpatient treatment versus continued standard treatment in children with cancer and low‐risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study. Pediatric Blood &amp; Cancer2012;59(3):423‐30. LüthiF , LeibundgutK , NiggliFK , NadalD , AebiC , BodmerN , et al. Serious medical complications in children with cancer and fever in chemotherapy‐induced neutropenia: results of the prospective multicenter SPOG 2003 FN study. Pediatric Blood &amp; Cancer2012;59(1):90‐5. ">Brack 2012*</a>; <a href="./references#CD003992-bbs2-0003" title="CornelyOA , WickeT , SeifertH , BetheU , SchwonzenM , ReichertD , et al. Once‐daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. International Journal of Hematology2004;79(1):74‐8. [MEDLINE: 14979482] ">Cornely 2003</a>; <a href="./references#CD003992-bbs2-0005" title="FreifeldA , MarchigianiD , WalshT , ChanockS , LewisL , HiemenzJ , et al. A double‐blind comparison of empirical oral and intravenous antibiotic therapy for low‐risk febrile patients with neutropenia during cancer chemotherapy. The New England Journal of Medicine1999;341(5):305‐11. ">Freifeld 1999</a>; <a href="./references#CD003992-bbs2-0007" title="GuptaA , SwaroopC , AgarwalaS , PandeyRM , BakhshiS . Randomized controlled trial comparing oral amoxicillin‐clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low‐risk febrile neutropenia. Journal of Pediatric Hematology/Oncology2009;31(9):635‐41. ">Gupta 2009*</a>; <a href="./references#CD003992-bbs2-0009" title="InnesHE , SmithDB , O'ReillySM , ClarkPI , KellyV , MarshallE . Oral antibiotics with early hospital discharge compared with inpatient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Data on file. ">Innes 2003</a>; <a href="./references#CD003992-bbs2-0010" title="KernWV , ComettaA , DeBockR , LangenaekenJ , PaesmansM , GayaH . Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. The New England Journal of Medicine1999;341:312‐8. ">Kern 1999</a>; <a href="./references#CD003992-bbs2-0012" title="MullenCA , PetropoulosD , RobertsWM , RyttingM , ZipfT , ChanKW , et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer1999;86:126‐34. MullenCA , PetropoulosD , RobertsWM , et al. Economic and resource utilization analysis of outpatient management of fever and neutropenia in low‐risk pediatric patients with cancer. Journal of Pediatric Hematology/Oncology1999;21:212‐8. ">Mullen 1999</a>; <a href="./references#CD003992-bbs2-0014" title="PaganiniHR , SarkisCM , DeMartinoMG , ZubizarretaPA , CasimirL , FernandezC , et al. Oral administration of cefixime to lower risk febrile neutropenic children with cancer. Cancer2000;88:2848‐52. ">Paganini 2000</a>). </p> <div class="table" id="CD003992-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Exclusion criteria of included trials (2004)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Evident infection</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Previous AB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Prolonged neutropeni</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Performance status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Active malignancy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BMT/PSCT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Other</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kern 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infected catheter or CNS infection, known bacterial /viral/fungal infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need of IV supportive therapy, expected to die within 48 hours, HIV, fever unrelated to infection and protocol violation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mullen 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A source of infection that required hospitalisation as: tunnelitis, pneumonia, perirectal cellulitis, typhlitis, resistant microorganism to one of the study's drugs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt;10% dehydration, bleeding requiring platelet transfusion,<br/> need for IV access, no access to telephone, &gt;1hour away from hospital unreliable caretaker </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paganini 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infected catheter, perineal/ facial cellulitis, uncontrolled local infection, positive blood cultures at 72 hours </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Persistance of fever &gt;48 hours, incorrectable bleeding; refractory hypoglycemia or hypocalcemia </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rubenstein 1993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Known resistant microorganism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na&lt;128, uncontrolled hypercalcemia, more than 30 miles away</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Samonis 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pneumonia, deep organ infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prior hospitalisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shenep 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pneumonia, clinical or radiographic evidence of focal bacterial infection, severe mucositis, positive blood cultures at 48 hours </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MRSA or P.Aeroginosa in any culture obtained in preceding 12weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Velasco1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Meningitis, pyelonephritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term central vein catheter</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Petrilli 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flaherty 1989</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Freifeld 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intravascular infection, tunnelitis, pneumonia, neurologic symtoms,</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment with Ca‐Mg or probenecid or alluporinol or theophylline, HIV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Giamarelou 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Suspected anaerobes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moribund and high probability of dying within 48 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hidalgo 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pneumonia, extensive cellulitis, meningitis, pyelonephritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clotting abnormalities, acidosis, hypercalcaemia, uncontrolled bleeding, live &gt;2h apart from hospital; Hx of tumour fever, other severe extra hematologic chemotherapy induced toxicity, no 24 hours home companion </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Innes 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tunnelitis, cellulitis, abcess, clinically documented infection likely to require prolonged antibiotic therapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for the use of G/GM‐CSF and cytokines; no responsible adult living with them (carer); </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Malik 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent FUO</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cornely 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excluded (except cotrimoxazole prophylaxis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>potential compromised absorption; inability to take oral medication; tenopathy, epilepsy; aplastic anaemia, acute leukaemia; septic shock or signs of sever infection; HIV carrier; serious concomitant disease, liver transaminase&gt; x5 of norm. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Niho 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent FUO; renal insufficiency; hepatic insufficiency; hypotension or peripheral circulatory failure; uncontrolled hypercalcaemia; altered sensorium; respiratory rate &gt;30 breaths/min; serum sodium &lt;128 mg/dl; inability to take oral medications; intestinal malabsorption </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paganini 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fascial, perineal, or catheter‐associated cellulites; uncontrolled local infection; positive blood cultures within the first 48 hours; infection with microorganisms known as resistant to ceftriaxone or ciprofloxacin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>severe comorbidity factors; respiratory failure</p> </td> </tr> </tbody> </table> </div> <p>Patients with any source of infection at presentation were included in six of the 'initial oral' trials (<a href="./references#CD003992-bbs2-0003" title="CornelyOA , WickeT , SeifertH , BetheU , SchwonzenM , ReichertD , et al. Once‐daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. International Journal of Hematology2004;79(1):74‐8. [MEDLINE: 14979482] ">Cornely 2003</a>; <a href="./references#CD003992-bbs2-0011" title="MalikIA , AbbasZ , KarimM . Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet1992;339:1092‐6. ">Malik 1992</a>; <a href="./references#CD003992-bbs2-0013" title="NihoS , OheY , GotoK , HOhmatsu , TMatsumoto , KKubota , et al. Randomized trial of oral versus intravenous antibiotics in low‐risk febrile neutropenic patients with lung cancer. Japanese Journal of Clinical Oncology2004;34(2):69‐73. [MEDLINE: 15067098] ">Niho 2004</a>; <a href="./references#CD003992-bbs2-0016" title="PetrilliAS , DantasLS , CamposMC , TanakaC , GinaniVC , SeberA . Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low‐risk pediatric oncology patients: randomized prospective trial. Medical and Pediatric Oncology2000;34:87‐91. ">Petrilli 2000</a>; <a href="./references#CD003992-bbs2-0018" title="RubensteinEB , RolstonK , BenjaminRS , LoewyJ , EscalanteC , ManzulloE , et al. Outpatient treatment of febrile episodes in low‐risk neutropenic patients with cancer. Cancer1993;71:3640‐6. ">Rubenstein 1993</a>; <a href="./references#CD003992-bbs2-0022" title="VelascoE , CostaMA , MartinsCA , NucciM . Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients. American Journal of Clinical Oncology‐Cancer Clinical Trials1995;18(5):429‐35. ">Velasco 1995</a>) and the 'sequential' studies. In the other studies patients with a specific source of infection were excluded: pneumonia was an exclusion criterion in six trials (<a href="./references#CD003992-bbs2-0005" title="FreifeldA , MarchigianiD , WalshT , ChanockS , LewisL , HiemenzJ , et al. A double‐blind comparison of empirical oral and intravenous antibiotic therapy for low‐risk febrile patients with neutropenia during cancer chemotherapy. The New England Journal of Medicine1999;341(5):305‐11. ">Freifeld 1999</a>; <a href="./references#CD003992-bbs2-0008" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer1999;85:213‐9. ">Hidalgo 1999</a>; <a href="./references#CD003992-bbs2-0009" title="InnesHE , SmithDB , O'ReillySM , ClarkPI , KellyV , MarshallE . Oral antibiotics with early hospital discharge compared with inpatient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Data on file. ">Innes 2003</a>; <a href="./references#CD003992-bbs2-0012" title="MullenCA , PetropoulosD , RobertsWM , RyttingM , ZipfT , ChanKW , et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer1999;86:126‐34. MullenCA , PetropoulosD , RobertsWM , et al. Economic and resource utilization analysis of outpatient management of fever and neutropenia in low‐risk pediatric patients with cancer. Journal of Pediatric Hematology/Oncology1999;21:212‐8. ">Mullen 1999</a>; <a href="./references#CD003992-bbs2-0019" title="AnaissieEJ , SamonisG , KalbakisK , GeorgouliasV . Therapy for low‐risk cancer patients with fever and neutropenia: results of a prospective, randomized trial with cost analysis. Interscience conference on antimicrobial agents and chemotherapy. 1997:LM‐51. ">Samonis 1997</a>; <a href="./references#CD003992-bbs2-0021" title="ShenepJL , FlynnPM , BakerDK , HetheringtonSV , HudsonMM , HughesWT , et al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clinical Infectious Disease2001;32:36‐43. ">Shenep 2001</a>); patients with infected intravascular catheters or tunnelitis were excluded in seven trials (<a href="./references#CD003992-bbs2-0005" title="FreifeldA , MarchigianiD , WalshT , ChanockS , LewisL , HiemenzJ , et al. A double‐blind comparison of empirical oral and intravenous antibiotic therapy for low‐risk febrile patients with neutropenia during cancer chemotherapy. The New England Journal of Medicine1999;341(5):305‐11. ">Freifeld 1999</a>; <a href="./references#CD003992-bbs2-0009" title="InnesHE , SmithDB , O'ReillySM , ClarkPI , KellyV , MarshallE . Oral antibiotics with early hospital discharge compared with inpatient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Data on file. ">Innes 2003</a>; <a href="./references#CD003992-bbs2-0010" title="KernWV , ComettaA , DeBockR , LangenaekenJ , PaesmansM , GayaH . Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. The New England Journal of Medicine1999;341:312‐8. ">Kern 1999</a>; <a href="./references#CD003992-bbs2-0012" title="MullenCA , PetropoulosD , RobertsWM , RyttingM , ZipfT , ChanKW , et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer1999;86:126‐34. MullenCA , PetropoulosD , RobertsWM , et al. Economic and resource utilization analysis of outpatient management of fever and neutropenia in low‐risk pediatric patients with cancer. Journal of Pediatric Hematology/Oncology1999;21:212‐8. ">Mullen 1999</a>; <a href="./references#CD003992-bbs2-0014" title="PaganiniHR , SarkisCM , DeMartinoMG , ZubizarretaPA , CasimirL , FernandezC , et al. Oral administration of cefixime to lower risk febrile neutropenic children with cancer. Cancer2000;88:2848‐52. ">Paganini 2000</a>; <a href="./references#CD003992-bbs2-0015" title="PaganiniH , GomezS , RuvinskyS , ZubizarretaP , LatellaA , FraquelliL , et al. Outpatient, sequential, parenteral‐oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single‐center, randomized, controlled trial in Argentina. Cancer2003;97(7):1775–80. [MEDLINE: 12655535] ">Paganini 2003</a>; <a href="./references#CD003992-bbs2-0021" title="ShenepJL , FlynnPM , BakerDK , HetheringtonSV , HudsonMM , HughesWT , et al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clinical Infectious Disease2001;32:36‐43. ">Shenep 2001</a>); perirectal or severe cellulitis was an exclusion criterion in six trials (<a href="./references#CD003992-bbs2-0008" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer1999;85:213‐9. ">Hidalgo 1999</a>; <a href="./references#CD003992-bbs2-0009" title="InnesHE , SmithDB , O'ReillySM , ClarkPI , KellyV , MarshallE . Oral antibiotics with early hospital discharge compared with inpatient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Data on file. ">Innes 2003</a>; <a href="./references#CD003992-bbs2-0012" title="MullenCA , PetropoulosD , RobertsWM , RyttingM , ZipfT , ChanKW , et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer1999;86:126‐34. MullenCA , PetropoulosD , RobertsWM , et al. Economic and resource utilization analysis of outpatient management of fever and neutropenia in low‐risk pediatric patients with cancer. Journal of Pediatric Hematology/Oncology1999;21:212‐8. ">Mullen 1999</a>; <a href="./references#CD003992-bbs2-0014" title="PaganiniHR , SarkisCM , DeMartinoMG , ZubizarretaPA , CasimirL , FernandezC , et al. Oral administration of cefixime to lower risk febrile neutropenic children with cancer. Cancer2000;88:2848‐52. ">Paganini 2000</a>; <a href="./references#CD003992-bbs2-0015" title="PaganiniH , GomezS , RuvinskyS , ZubizarretaP , LatellaA , FraquelliL , et al. Outpatient, sequential, parenteral‐oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single‐center, randomized, controlled trial in Argentina. Cancer2003;97(7):1775–80. [MEDLINE: 12655535] ">Paganini 2003</a>; <a href="./references#CD003992-bbs2-0021" title="ShenepJL , FlynnPM , BakerDK , HetheringtonSV , HudsonMM , HughesWT , et al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clinical Infectious Disease2001;32:36‐43. ">Shenep 2001</a>); <a href="./references#CD003992-bbs2-0010" title="KernWV , ComettaA , DeBockR , LangenaekenJ , PaesmansM , GayaH . Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. The New England Journal of Medicine1999;341:312‐8. ">Kern 1999</a> excluded known bacterial, viral or fungal infection; and <a href="./references#CD003992-bbs2-0014" title="PaganiniHR , SarkisCM , DeMartinoMG , ZubizarretaPA , CasimirL , FernandezC , et al. Oral administration of cefixime to lower risk febrile neutropenic children with cancer. Cancer2000;88:2848‐52. ">Paganini 2000</a> excluded uncontrolled local infection. In one trial (<a href="./references#CD003992-bbs2-0020" title="SebbanC , DussartS , FuhrmannC , GhesquieresH , RodriguesI , GeoffroisL , et al. Oral moxifloxacin or intravenous ceftriaxone for the treatment of low‐risk neutropenic fever in cancer patients suitable for early hospital discharge. Supportive Care in Cancer2008;16(9):1017‐23. ">Sebban 2009*</a>) a MASCC score of 21 or lower was an inclusion criterion. </p> <p>The oral antibiotics differed between trials: antipneumococcal quinolones in two trials (<a href="./references#CD003992-bbs2-0015" title="PaganiniH , GomezS , RuvinskyS , ZubizarretaP , LatellaA , FraquelliL , et al. Outpatient, sequential, parenteral‐oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single‐center, randomized, controlled trial in Argentina. Cancer2003;97(7):1775–80. [MEDLINE: 12655535] ">Paganini 2003</a>; <a href="./references#CD003992-bbs2-0020" title="SebbanC , DussartS , FuhrmannC , GhesquieresH , RodriguesI , GeoffroisL , et al. Oral moxifloxacin or intravenous ceftriaxone for the treatment of low‐risk neutropenic fever in cancer patients suitable for early hospital discharge. Supportive Care in Cancer2008;16(9):1017‐23. ">Sebban 2009*</a>), other quinolones in 10 trials (<a href="./references#CD003992-bbs2-0001" title="BrackE , BodmerN , SimonA , LeibundgutK , KühneT , NiggliFK , et al. First‐day step‐down to oral outpatient treatment versus continued standard treatment in children with cancer and low‐risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study. Pediatric Blood &amp; Cancer2012;59(3):423‐30. LüthiF , LeibundgutK , NiggliFK , NadalD , AebiC , BodmerN , et al. Serious medical complications in children with cancer and fever in chemotherapy‐induced neutropenia: results of the prospective multicenter SPOG 2003 FN study. Pediatric Blood &amp; Cancer2012;59(1):90‐5. ">Brack 2012*</a>; <a href="./references#CD003992-bbs2-0002" title="CagolAR , Castro JuniorCG , MartinsMC , MachadoAL , RibeiroRC , GregianinLJ , et al. Oral vs. intravenous empirical antimicrobial therapy in febrile neutropenic patients receiving childhood cancer chemotherapy. Jornal de Pediatria2009;85(6):531‐5. ">Cagol 2009*</a>; <a href="./references#CD003992-bbs2-0004" title="FlahertyJP , WaitleyD , EdlinB , GeorgeD , ArnowP , O'KeefeP , et al. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. The American Journal of Medicine1989;87 Suppl:278‐82. ">Flaherty 1989</a>; <a href="./references#CD003992-bbs2-0006" title="GiamarellouH , BassarisHP , PetrikkosG , BuschW , VoulgarelisM , AntoniadouA , et al. Monotherapy with intravenous followed by oral high‐dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrobial Agents and Chemotherapy2000;44:3264‐71. ">Giamarellou 2000</a>; <a href="./references#CD003992-bbs2-0007" title="GuptaA , SwaroopC , AgarwalaS , PandeyRM , BakhshiS . Randomized controlled trial comparing oral amoxicillin‐clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low‐risk febrile neutropenia. Journal of Pediatric Hematology/Oncology2009;31(9):635‐41. ">Gupta 2009*</a>; <a href="./references#CD003992-bbs2-0008" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer1999;85:213‐9. ">Hidalgo 1999</a>; <a href="./references#CD003992-bbs2-0011" title="MalikIA , AbbasZ , KarimM . Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet1992;339:1092‐6. ">Malik 1992</a>; <a href="./references#CD003992-bbs2-0012" title="MullenCA , PetropoulosD , RobertsWM , RyttingM , ZipfT , ChanKW , et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer1999;86:126‐34. MullenCA , PetropoulosD , RobertsWM , et al. Economic and resource utilization analysis of outpatient management of fever and neutropenia in low‐risk pediatric patients with cancer. Journal of Pediatric Hematology/Oncology1999;21:212‐8. ">Mullen 1999</a>; <a href="./references#CD003992-bbs2-0016" title="PetrilliAS , DantasLS , CamposMC , TanakaC , GinaniVC , SeberA . Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low‐risk pediatric oncology patients: randomized prospective trial. Medical and Pediatric Oncology2000;34:87‐91. ">Petrilli 2000</a>). Quinolones were given in combination with ampicillin‐clavulanate, ampicillin‐sulbactam, or penicillin V in nine trials (<a href="./references#CD003992-bbs2-0001" title="BrackE , BodmerN , SimonA , LeibundgutK , KühneT , NiggliFK , et al. First‐day step‐down to oral outpatient treatment versus continued standard treatment in children with cancer and low‐risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study. Pediatric Blood &amp; Cancer2012;59(3):423‐30. LüthiF , LeibundgutK , NiggliFK , NadalD , AebiC , BodmerN , et al. Serious medical complications in children with cancer and fever in chemotherapy‐induced neutropenia: results of the prospective multicenter SPOG 2003 FN study. Pediatric Blood &amp; Cancer2012;59(1):90‐5. ">Brack 2012*</a>; <a href="./references#CD003992-bbs2-0002" title="CagolAR , Castro JuniorCG , MartinsMC , MachadoAL , RibeiroRC , GregianinLJ , et al. Oral vs. intravenous empirical antimicrobial therapy in febrile neutropenic patients receiving childhood cancer chemotherapy. Jornal de Pediatria2009;85(6):531‐5. ">Cagol 2009*</a>; <a href="./references#CD003992-bbs2-0005" title="FreifeldA , MarchigianiD , WalshT , ChanockS , LewisL , HiemenzJ , et al. A double‐blind comparison of empirical oral and intravenous antibiotic therapy for low‐risk febrile patients with neutropenia during cancer chemotherapy. The New England Journal of Medicine1999;341(5):305‐11. ">Freifeld 1999</a>; <a href="./references#CD003992-bbs2-0007" title="GuptaA , SwaroopC , AgarwalaS , PandeyRM , BakhshiS . Randomized controlled trial comparing oral amoxicillin‐clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low‐risk febrile neutropenia. Journal of Pediatric Hematology/Oncology2009;31(9):635‐41. ">Gupta 2009*</a>; <a href="./references#CD003992-bbs2-0009" title="InnesHE , SmithDB , O'ReillySM , ClarkPI , KellyV , MarshallE . Oral antibiotics with early hospital discharge compared with inpatient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Data on file. ">Innes 2003</a>; <a href="./references#CD003992-bbs2-0010" title="KernWV , ComettaA , DeBockR , LangenaekenJ , PaesmansM , GayaH . Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. The New England Journal of Medicine1999;341:312‐8. ">Kern 1999</a>; <a href="./references#CD003992-bbs2-0013" title="NihoS , OheY , GotoK , HOhmatsu , TMatsumoto , KKubota , et al. Randomized trial of oral versus intravenous antibiotics in low‐risk febrile neutropenic patients with lung cancer. Japanese Journal of Clinical Oncology2004;34(2):69‐73. [MEDLINE: 15067098] ">Niho 2004</a>; <a href="./references#CD003992-bbs2-0017" title="RolstonK , RubensteinE , EltingL , EscalanteC , ManzulloE , BodeyGP . Ambulatory management of febrile episodes in low‐risk neutropenic patients. Interscience conference on antimicrobial agents and chemotherapy. 1995:LM81. ">Rolston 1995</a>; <a href="./references#CD003992-bbs2-0019" title="AnaissieEJ , SamonisG , KalbakisK , GeorgouliasV . Therapy for low‐risk cancer patients with fever and neutropenia: results of a prospective, randomized trial with cost analysis. Interscience conference on antimicrobial agents and chemotherapy. 1997:LM‐51. ">Samonis 1997</a>; <a href="./references#CD003992-bbs2-0022" title="VelascoE , CostaMA , MartinsCA , NucciM . Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients. American Journal of Clinical Oncology‐Cancer Clinical Trials1995;18(5):429‐35. ">Velasco 1995</a>) and in combination with clindamycin in one trial (<a href="./references#CD003992-bbs2-0018" title="RubensteinEB , RolstonK , BenjaminRS , LoewyJ , EscalanteC , ManzulloE , et al. Outpatient treatment of febrile episodes in low‐risk neutropenic patients with cancer. Cancer1993;71:3640‐6. ">Rubenstein 1993</a>). The antibiotics given orally were different in most studies from the drugs given intravenously. </p> <p>The setting of therapy also varied. All patients were treated as outpatients in six trials (<a href="./references#CD003992-bbs2-0003" title="CornelyOA , WickeT , SeifertH , BetheU , SchwonzenM , ReichertD , et al. Once‐daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. International Journal of Hematology2004;79(1):74‐8. [MEDLINE: 14979482] ">Cornely 2003</a>; <a href="./references#CD003992-bbs2-0007" title="GuptaA , SwaroopC , AgarwalaS , PandeyRM , BakhshiS . Randomized controlled trial comparing oral amoxicillin‐clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low‐risk febrile neutropenia. Journal of Pediatric Hematology/Oncology2009;31(9):635‐41. ">Gupta 2009*</a>; <a href="./references#CD003992-bbs2-0012" title="MullenCA , PetropoulosD , RobertsWM , RyttingM , ZipfT , ChanKW , et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer1999;86:126‐34. MullenCA , PetropoulosD , RobertsWM , et al. Economic and resource utilization analysis of outpatient management of fever and neutropenia in low‐risk pediatric patients with cancer. Journal of Pediatric Hematology/Oncology1999;21:212‐8. ">Mullen 1999</a>; <a href="./references#CD003992-bbs2-0015" title="PaganiniH , GomezS , RuvinskyS , ZubizarretaP , LatellaA , FraquelliL , et al. Outpatient, sequential, parenteral‐oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single‐center, randomized, controlled trial in Argentina. Cancer2003;97(7):1775–80. [MEDLINE: 12655535] ">Paganini 2003</a>; <a href="./references#CD003992-bbs2-0016" title="PetrilliAS , DantasLS , CamposMC , TanakaC , GinaniVC , SeberA . Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low‐risk pediatric oncology patients: randomized prospective trial. Medical and Pediatric Oncology2000;34:87‐91. ">Petrilli 2000</a>; <a href="./references#CD003992-bbs2-0017" title="RolstonK , RubensteinE , EltingL , EscalanteC , ManzulloE , BodeyGP . Ambulatory management of febrile episodes in low‐risk neutropenic patients. Interscience conference on antimicrobial agents and chemotherapy. 1995:LM81. ">Rolston 1995</a>; <a href="./references#CD003992-bbs2-0018" title="RubensteinEB , RolstonK , BenjaminRS , LoewyJ , EscalanteC , ManzulloE , et al. Outpatient treatment of febrile episodes in low‐risk neutropenic patients with cancer. Cancer1993;71:3640‐6. ">Rubenstein 1993</a>). Patients randomised to oral therapy were treated as outpatients while the control group was treated in hospital in three trials (<a href="./references#CD003992-bbs2-0008" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer1999;85:213‐9. ">Hidalgo 1999</a>; <a href="./references#CD003992-bbs2-0009" title="InnesHE , SmithDB , O'ReillySM , ClarkPI , KellyV , MarshallE . Oral antibiotics with early hospital discharge compared with inpatient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Data on file. ">Innes 2003</a>; <a href="./references#CD003992-bbs2-0019" title="AnaissieEJ , SamonisG , KalbakisK , GeorgouliasV . Therapy for low‐risk cancer patients with fever and neutropenia: results of a prospective, randomized trial with cost analysis. Interscience conference on antimicrobial agents and chemotherapy. 1997:LM‐51. ">Samonis 1997</a>). Therapy was initiated in hospital and continued at home in two trials (<a href="./references#CD003992-bbs2-0001" title="BrackE , BodmerN , SimonA , LeibundgutK , KühneT , NiggliFK , et al. First‐day step‐down to oral outpatient treatment versus continued standard treatment in children with cancer and low‐risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study. Pediatric Blood &amp; Cancer2012;59(3):423‐30. LüthiF , LeibundgutK , NiggliFK , NadalD , AebiC , BodmerN , et al. Serious medical complications in children with cancer and fever in chemotherapy‐induced neutropenia: results of the prospective multicenter SPOG 2003 FN study. Pediatric Blood &amp; Cancer2012;59(1):90‐5. ">Brack 2012*</a>; <a href="./references#CD003992-bbs2-0020" title="SebbanC , DussartS , FuhrmannC , GhesquieresH , RodriguesI , GeoffroisL , et al. Oral moxifloxacin or intravenous ceftriaxone for the treatment of low‐risk neutropenic fever in cancer patients suitable for early hospital discharge. Supportive Care in Cancer2008;16(9):1017‐23. ">Sebban 2009*</a>). In the rest of the trials all patients were treated in hospital. </p> <p>With both regimens few studies had high mortality rates (5% to 8.8%) (<a href="./references#CD003992-bbs2-0004" title="FlahertyJP , WaitleyD , EdlinB , GeorgeD , ArnowP , O'KeefeP , et al. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. The American Journal of Medicine1989;87 Suppl:278‐82. ">Flaherty 1989</a>; <a href="./references#CD003992-bbs2-0006" title="GiamarellouH , BassarisHP , PetrikkosG , BuschW , VoulgarelisM , AntoniadouA , et al. Monotherapy with intravenous followed by oral high‐dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrobial Agents and Chemotherapy2000;44:3264‐71. ">Giamarellou 2000</a>; <a href="./references#CD003992-bbs2-0010" title="KernWV , ComettaA , DeBockR , LangenaekenJ , PaesmansM , GayaH . Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. The New England Journal of Medicine1999;341:312‐8. ">Kern 1999</a>; <a href="./references#CD003992-bbs2-0011" title="MalikIA , AbbasZ , KarimM . Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet1992;339:1092‐6. ">Malik 1992</a>). This can be explained by the design of the trials: randomisation of patients not episodes (<a href="./references#CD003992-bbs2-0006" title="GiamarellouH , BassarisHP , PetrikkosG , BuschW , VoulgarelisM , AntoniadouA , et al. Monotherapy with intravenous followed by oral high‐dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrobial Agents and Chemotherapy2000;44:3264‐71. ">Giamarellou 2000</a>; <a href="./references#CD003992-bbs2-0010" title="KernWV , ComettaA , DeBockR , LangenaekenJ , PaesmansM , GayaH . Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. The New England Journal of Medicine1999;341:312‐8. ">Kern 1999</a>; <a href="./references#CD003992-bbs2-0011" title="MalikIA , AbbasZ , KarimM . Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet1992;339:1092‐6. ">Malik 1992</a>), a longer follow‐up period (<a href="./references#CD003992-bbs2-0010" title="KernWV , ComettaA , DeBockR , LangenaekenJ , PaesmansM , GayaH . Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. The New England Journal of Medicine1999;341:312‐8. ">Kern 1999</a>), and not applying most low risk criteria for inclusion (<a href="./references#CD003992-bbs2-0011" title="MalikIA , AbbasZ , KarimM . Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet1992;339:1092‐6. ">Malik 1992</a>). </p> </section> <section id="CD003992-sec-0051"> <h4 class="title">Excluded studies</h4> <p>Fifty‐eight trials were excluded from this review (<a href="./references#CD003992-sec-0088" title="">Characteristics of excluded studies</a>). Reasons for their exclusion were the following. </p> <p> <ul id="CD003992-list-0009"> <li> <p>Not randomised trials (<a href="./references#CD003992-bbs2-0024" title="AmmannRA . Outpatient, sequential, parenteral‐oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single‐center, randomized, controlled trial in Argentina. Cancer2004;100(7):1547; author reply 1547‐8. ">Ammann 2004</a>; <a href="./references#CD003992-bbs2-0025" title="AquinoVM , BuchananGR , TkaczewskiI , MustafaMM . Safety of early hospital discharge of selected febrile children and adolescents with cancer with prolonged neutropenia. Medical and Pediatric Oncology1997;28:191‐5. ">Aquino 1997</a>; <a href="./references#CD003992-bbs2-0026" title="AquinoVM , HerreraL , SandlerES , BuchananGR . Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer. Cancer2000;88:1710‐4. ">Aquino 2000</a>; <a href="./references#CD003992-bbs2-0027" title="BashRO , KatzJA , CashJV , BuchananGR . Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer1994;74(1):189‐96. ">Bash 1994</a>; <a href="./references#CD003992-bbs2-0028" title="BerrahalF , BaumeD , BurteyS , MazzerboF , ZanluccaS , DemichelisC . A study of intravenous ticarcillin/clavulanic acid and oral ciprofloxacin in the treatment of febrile neutropenic patients. Journal de Pharmacie Clinique1996;15(Special issue):74‐7. ">Berrahal 1996</a>; <a href="./references#CD003992-bbs2-0029" title="ChamilosG , BamiasA , EfstathiouE , ZorzouPM , KastritisE , KostisE , et al. Outpatient treatment of low‐risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer2005;103(12):2629‐35. [MEDLINE: 15856427] ">Chamilos 2005</a>; <a href="./references#CD003992-bbs2-0033" title="CornelissenJJ , Rozenberg‐ArskaM , DekkerAW . Discontinuation of intravenous antibiotic therapy during persistent neutropenia in patients receiving prophylaxis with oral ciprofloxacin. Clinical Infectious Diseases1995;21:1300‐2. ">Cornelissen 1995</a>; <a href="./references#CD003992-bbs2-0040" title="Gardembas‐PainM , DesablensB , SensebeL , LamyT , GhandourC , BoassonM . Home treatment of febrile neutropenia: an empirical oral antibiotic regimen. Annals of Oncology1991;2:485‐7. ">Gardembas‐Pain 1991</a>; <a href="./references#CD003992-bbs2-0035" title="EscalanteCP , WeiserMA , ManzulloE , BenjaminR , RiveraE , LamT , et al. Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients. Supportive Care in Cancer2004;12(9):657‐62. ">Escalante 2004</a>; <a href="./references#CD003992-bbs2-0039" title="FreifeldAG , SepkowitzKA . No place like home? Outpatient management of patients with febrile neutropenia and low risk. Journal of Clinical Oncology2011;20(30):3952‐4. ">Freifeld 2011</a>; <a href="./references#CD003992-bbs2-0043" title="HorowitzHW , HolmgrenD , SeiterK . Stepdown single agent antibiotic therapy for the management of the high risk neutropenic adult with hematologic malignancies. Leukemia and Lymphoma1996;23(1‐2):159‐63. ">Horowitz 1996</a>; <a href="./references#CD003992-bbs2-0050" title="LauRC , DoyleJJ , FreedmanMH , KingSM , RichardsonSE . Early discharge of pediatric febrile neutropenic cancer patients by substitution of oral for intravenous antibiotics. Journal of Pediatric Hematology/Oncology1994;11:417‐21. ">Lau 1994</a>; <a href="./references#CD003992-bbs2-0053" title="MalikIA , KhanWA , AzizZ , KarimM . Self‐administered antibiotic therapy for chemotherapy‐induced, low‐risk febrile neutropenia in patients with nonhematologic neoplasms. Clinical Infectious Diseases1994;19:522‐7. ">Malik 1994</a>; <a href="./references#CD003992-bbs2-0055" title="MalikIA . Out‐patient management of febrile neutropenia in indigent paediatric patients. Annals of the Academy of Medicine, Singapore1997;26:742‐6. ">Malik 1997</a>; <a href="./references#CD003992-bbs2-0059" title="Montalar SalcedoJ , Oltra FerrandoA , Segura HuertaA , Santaballa BertranA , Yuste IzquierdoA , Aparicio UrtasunJ . Ofloxacin as monotherapy in the treatment of neutropenic fever. Oncologia1999;22(8):42‐7. ">Montalar Salcedo1999</a>; <a href="./references#CD003992-bbs2-0056" title="MarraCA , FrighettoL , QuaiaCB , et al. A new ciprofloxacin stepdown program in the treatment of high‐risk febrile neutropenia: a clinical and economic analysis. Pharmacotherapy2000;20:931‐40. ">Marra 2000</a>; <a href="./references#CD003992-bbs2-0061" title="MustafaMM , AquinoVM , PappoA , TkaczewskiI , BuchananGR . A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia. The Journal of Pediatrics1996;128(6):847‐9. ">Mustafa 1996</a>; <a href="./references#CD003992-bbs2-0062" title="Nepokul'chitskaiaNV , TimakovAM , KondratchikKL , MakhortykhT , TarasovaIS , ErinaTA . [Cephalosporins in the treatment of children with oncohematologic diseases]. Antibiotiki i Khimioterapiia (Moskva)1998;43:30‐2. ">Nepokul'chitskaia</a>; <a href="./references#CD003992-bbs2-0064" title="PaganiniH , Rodriguez‐BrieshckeTR , ZubizarretaP , LatellaA , FirpoV , FernandezC . Validation of lower risk mortality profile in pediatric febrile neutropenia during cancer chemotherapy. Medicina2001;61(1):63‐6. ">Paganini 2001b</a>; <a href="./references#CD003992-bbs2-0065" title="PapadimitrisC , DimopoulosMA , KostisE , PapadimitriouC , AnagnostopoulosA , AlexopoulosG , et al. Outpatient treatment of neutropenic fever with oral antibiotics and granulocyte colony‐stimulating factor. Oncology1999;57:127‐30. ">Papadimitris 1999</a>; <a href="./references#CD003992-bbs2-0079" title="VallejoC , CaballeroMD , Garcia‐SanzR , HernandezJM , VazquezL , CanizoMC , et al. Sequential intravenous‐oral ciprofloxacin plus amoxycillin/clavulanic acid shortens hospital stay in infected non severe neutropenic patients. Hematology &amp; Cell Therapy1997;39(5):223‐7. ">Vallejo 1997</a>; <a href="./references#CD003992-bbs2-0080" title="WackerP , HalperinDS , WyssM , HumbertJ . Early hospital discharge of children with fever and neutropenia: a prospective study. Journal of Pediatric Hematology/Oncology1997;19(3):208‐11. ">Wacker 1997</a>). </p> </li> <li> <p>Sequential oral ‐ intravenous antibiotics were used for all the patients in both trial arms (<a href="./references#CD003992-bbs2-0063" title="PaganiniH , Rodriguez‐BrieshckeT , ZubizarretaP , LatellaA , FirpoV , CasimirL , et al. Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia. Cancer2001;91:1563‐7. ">Paganini 2001a</a>). </p> </li> <li> <p>No intravenous treatment arm (<a href="./references#CD003992-bbs2-0054" title="MalikIA , AzizZ , KhanWA . A randomized trial to evaluate the role of ofloxacin in the out‐patient management of neutropenic febrile patients. Annals of Oncology1992;3 Suppl:197. MalikIA , KhanWA , KarimM , AzizZ , KhanMA . Feasibility of outpatient management of fever in cancer patients with low‐risk neutropenia: results of a prospective randomized trial. The American Journal of Medicine1995;98:224‐31. ">Malik 1995</a>). All patients received oral antibiotics, and were randomised to outpatient versus inpatient therapy. </p> </li> <li> <p>Sequential oral antibiotic therapy was compared to no treatment (or placebo) (<a href="./references#CD003992-bbs2-0048" title="KlaassenRJ , AllenU , DoyleJJ . Randomized placebo‐controlled trial of oral antibiotics in pediatric oncology patients at low‐risk with fever and neutropenia. Journal of Pediatric Hematology/Oncology2000;22:405‐11. ">Klaassen 2000</a>; <a href="./references#CD003992-bbs2-0071" title="SantolayaME , VillarroelM , AvendanoLF , CofreJ . Discontinuation of antimicrobial therapy for febrile, neutropenic children with cancer: a prospective study. Clinical Infectious Diseases1997;25(1):92‐7. ">Santolaya 1997</a>). </p> </li> <li> <p>No oral treatment arm (<a href="./references#CD003992-bbs2-0044" title="International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. JAMA1994;272:1183‐9. ">IATCG‐EORTC 1994</a>; <a href="./references#CD003992-bbs2-0047" title="KibblerCC , PomroyL , SageRJ , MannanP , NooneP , PrenticeHG . The use of ciprofloxacin in the treatment of febrile neutropenic patients. Proceedings of the 33rd European Congress of Clinical Microbiology. 1987 11‐14 May. ">Kibbler 1987</a>; <a href="./references#CD003992-bbs2-0057" title="MeunierF , ZinnerSH , GayaH , CalandraT , ViscoliC , KlasterskyJ , et al. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group. Antimicrobial Agents and Chemotherapy1991;35(5):873‐8. ">Meunier 1991</a>; <a href="./references#CD003992-bbs2-0068" title="RapoportBL , SussmannO , HerreraMV , SchlaefferF , OteroJC , PavlovskyS , et al. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge versus standard in‐patient care. Chemotherapy1999;45(6):466‐76. ">Rapoport 1999</a>; <a href="./references#CD003992-bbs2-0072" title="SantolayaME , AlvarezAM , AvilesCL , BeckerA , CofreJ , CumsilleMA , et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. Journal of Clinical Oncology2004;22(18):3784‐9. ">Santolaya 2004</a>; <a href="./references#CD003992-bbs2-0073" title="SatoT , KobayashiR , YasudaK , KanedaM , IguchiA , KobayashiK . A prospective, randomized study comparing cefozopran with piperacillin‐tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders. Pediatric Blood &amp; Cancer2008;51(6):774‐7. ">Sato 2008</a>). </p> </li> <li> <p>Review (<a href="./references#CD003992-bbs2-0031" title="ComettaA , KernW . [Treatment with oral antibiotics of febrile neutropenia in onco‐haematology. The experience of the EORTC antimicrobial group]. Presse Medicale2004;33(5):327‐9. ">Cometta 2004</a>; <a href="./references#CD003992-bbs2-0032" title="Cooper MR. Durand CR. Beaulac MT. SteinbergM . Single‐agent, broad‐spectrum fluoroquinolones for the outpatient treatment of low‐risk febrile neutropenia. Annals of Pharmacotherapy2011;45(9):1094‐102. ">Copper 2011</a>; <a href="./references#CD003992-bbs2-0037" title="FreifeldA , PizzoP . Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients. The Pediatric Infectious Disease Journal1997;16:140‐5; discussion 145‐6, 160‐2. ">Freifeld 1997</a>; <a href="./references#CD003992-bbs2-0051" title="LevergerG . [Outpatient antibiotherapy in children with neutropenia and fever. A review of the literature.]. Presse Medicale2004;33(5):330‐7. ">Leverger 2004</a>; <a href="./references#CD003992-bbs2-0060" title="MullenCA . Which children with fever and neutropenia can be safely treated as outpatients?. British Journal of Haematology2001;112:832‐7. ">Mullen 2001</a>; <a href="./references#CD003992-bbs2-0076" title="TamuraK . Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group. International Journal of Antimicrobial Agents2005;26 Suppl 2:S123‐7; discussion S133‐40. ">Tamura 2005</a>). </p> </li> <li> <p>One study (<a href="./references#CD003992-bbs2-0058" title="MinottiV , GentileG , BucaneveG , IoriAP , MicozziA , CavicchiF , et al. Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment. Supportive Care in Cancer1999;7:134‐9. ">Minotti 1999</a>) included all patients with fever post‐chemotherapy, neutropenic and non‐neutropenic, and did not report the outcomes of neutropenic patients separately. </p> </li> <li> <p>Prophylaxis (<a href="./references#CD003992-bbs2-0077" title="TimmersGJ , Simoons‐SmitAM , LeidekkerME , JanssenJJ , Vandenbroucke‐GraulsCM , HuijgensPC . Levofloxacin vs. ciprofloxacin plus phenethicillin for the prevention of bacterial infections in patients with haematological malignancies. Clinical Microbiology and Infection2007;13(5):497‐503. ">Timmers 2007</a>). </p> </li> </ul> </p> </section> </section> <section id="CD003992-sec-0052"> <h3 class="title">Risk of bias in included studies</h3> <p>Adequate allocation concealment was reported in six trials (<a href="./references#CD003992-bbs2-0001" title="BrackE , BodmerN , SimonA , LeibundgutK , KühneT , NiggliFK , et al. First‐day step‐down to oral outpatient treatment versus continued standard treatment in children with cancer and low‐risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study. Pediatric Blood &amp; Cancer2012;59(3):423‐30. LüthiF , LeibundgutK , NiggliFK , NadalD , AebiC , BodmerN , et al. Serious medical complications in children with cancer and fever in chemotherapy‐induced neutropenia: results of the prospective multicenter SPOG 2003 FN study. Pediatric Blood &amp; Cancer2012;59(1):90‐5. ">Brack 2012*</a>; <a href="./references#CD003992-bbs2-0002" title="CagolAR , Castro JuniorCG , MartinsMC , MachadoAL , RibeiroRC , GregianinLJ , et al. Oral vs. intravenous empirical antimicrobial therapy in febrile neutropenic patients receiving childhood cancer chemotherapy. Jornal de Pediatria2009;85(6):531‐5. ">Cagol 2009*</a>; <a href="./references#CD003992-bbs2-0003" title="CornelyOA , WickeT , SeifertH , BetheU , SchwonzenM , ReichertD , et al. Once‐daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. International Journal of Hematology2004;79(1):74‐8. [MEDLINE: 14979482] ">Cornely 2003</a>; <a href="./references#CD003992-bbs2-0006" title="GiamarellouH , BassarisHP , PetrikkosG , BuschW , VoulgarelisM , AntoniadouA , et al. Monotherapy with intravenous followed by oral high‐dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrobial Agents and Chemotherapy2000;44:3264‐71. ">Giamarellou 2000</a>; <a href="./references#CD003992-bbs2-0010" title="KernWV , ComettaA , DeBockR , LangenaekenJ , PaesmansM , GayaH . Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. The New England Journal of Medicine1999;341:312‐8. ">Kern 1999</a>; <a href="./references#CD003992-bbs2-0020" title="SebbanC , DussartS , FuhrmannC , GhesquieresH , RodriguesI , GeoffroisL , et al. Oral moxifloxacin or intravenous ceftriaxone for the treatment of low‐risk neutropenic fever in cancer patients suitable for early hospital discharge. Supportive Care in Cancer2008;16(9):1017‐23. ">Sebban 2009*</a>); information regarding adequate allocation concealment was provided by the contact authors in five other trials (<a href="./references#CD003992-bbs2-0008" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer1999;85:213‐9. ">Hidalgo 1999</a>; <a href="./references#CD003992-bbs2-0009" title="InnesHE , SmithDB , O'ReillySM , ClarkPI , KellyV , MarshallE . Oral antibiotics with early hospital discharge compared with inpatient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Data on file. ">Innes 2003</a>; <a href="./references#CD003992-bbs2-0014" title="PaganiniHR , SarkisCM , DeMartinoMG , ZubizarretaPA , CasimirL , FernandezC , et al. Oral administration of cefixime to lower risk febrile neutropenic children with cancer. Cancer2000;88:2848‐52. ">Paganini 2000</a>; <a href="./references#CD003992-bbs2-0021" title="ShenepJL , FlynnPM , BakerDK , HetheringtonSV , HudsonMM , HughesWT , et al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clinical Infectious Disease2001;32:36‐43. ">Shenep 2001</a>; <a href="./references#CD003992-bbs2-0022" title="VelascoE , CostaMA , MartinsCA , NucciM . Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients. American Journal of Clinical Oncology‐Cancer Clinical Trials1995;18(5):429‐35. ">Velasco 1995</a>). Two trials (<a href="./references#CD003992-bbs2-0011" title="MalikIA , AbbasZ , KarimM . Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet1992;339:1092‐6. ">Malik 1992</a>; <a href="./references#CD003992-bbs2-0013" title="NihoS , OheY , GotoK , HOhmatsu , TMatsumoto , KKubota , et al. Randomized trial of oral versus intravenous antibiotics in low‐risk febrile neutropenic patients with lung cancer. Japanese Journal of Clinical Oncology2004;34(2):69‐73. [MEDLINE: 15067098] ">Niho 2004</a>) reported how the allocation concealment was undertaken but its adequacy was unclear. These trials used sealed envelopes, however, no mention was made about whether the envelopes were opaque and the trials were assessed as at unclear risk of bias. There was no information regarding concealment of allocation in the other nine trials. Two trials were double blinded (<a href="./references#CD003992-bbs2-0002" title="CagolAR , Castro JuniorCG , MartinsMC , MachadoAL , RibeiroRC , GregianinLJ , et al. Oral vs. intravenous empirical antimicrobial therapy in febrile neutropenic patients receiving childhood cancer chemotherapy. Jornal de Pediatria2009;85(6):531‐5. ">Cagol 2009*</a>; <a href="./references#CD003992-bbs2-0005" title="FreifeldA , MarchigianiD , WalshT , ChanockS , LewisL , HiemenzJ , et al. A double‐blind comparison of empirical oral and intravenous antibiotic therapy for low‐risk febrile patients with neutropenia during cancer chemotherapy. The New England Journal of Medicine1999;341(5):305‐11. ">Freifeld 1999</a>) and in one the outcomes assessors were blinded to the treatment arm (<a href="./references#CD003992-bbs2-0010" title="KernWV , ComettaA , DeBockR , LangenaekenJ , PaesmansM , GayaH . Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. The New England Journal of Medicine1999;341:312‐8. ">Kern 1999</a>). Blinding was not specified in the other trials. </p> <p>Duration of follow‐up was predefined only in three trials (<a href="./references#CD003992-bbs2-0003" title="CornelyOA , WickeT , SeifertH , BetheU , SchwonzenM , ReichertD , et al. Once‐daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. International Journal of Hematology2004;79(1):74‐8. [MEDLINE: 14979482] ">Cornely 2003</a>; <a href="./references#CD003992-bbs2-0010" title="KernWV , ComettaA , DeBockR , LangenaekenJ , PaesmansM , GayaH . Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. The New England Journal of Medicine1999;341:312‐8. ">Kern 1999</a> (reported); <a href="./references#CD003992-bbs2-0014" title="PaganiniHR , SarkisCM , DeMartinoMG , ZubizarretaPA , CasimirL , FernandezC , et al. Oral administration of cefixime to lower risk febrile neutropenic children with cancer. Cancer2000;88:2848‐52. ">Paganini 2000</a> (data from author)). In the other trials follow‐up varied according to the length of the neutropenic febrile episode. In two trials (<a href="./references#CD003992-bbs2-0006" title="GiamarellouH , BassarisHP , PetrikkosG , BuschW , VoulgarelisM , AntoniadouA , et al. Monotherapy with intravenous followed by oral high‐dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrobial Agents and Chemotherapy2000;44:3264‐71. ">Giamarellou 2000</a>; <a href="./references#CD003992-bbs2-0009" title="InnesHE , SmithDB , O'ReillySM , ClarkPI , KellyV , MarshallE . Oral antibiotics with early hospital discharge compared with inpatient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Data on file. ">Innes 2003</a>) the patients were followed for a predefined time after resolution of fever. In the other trials patients were followed until the end of the febrile neutropenic episode or until the end of antibiotic treatment. </p> <p>Five per cent (median, range 0 to 0.18) of the patients were excluded from the final analysis. One trial provided no information about exclusions from the final analysis (<a href="./references#CD003992-bbs2-0017" title="RolstonK , RubensteinE , EltingL , EscalanteC , ManzulloE , BodeyGP . Ambulatory management of febrile episodes in low‐risk neutropenic patients. Interscience conference on antimicrobial agents and chemotherapy. 1995:LM81. ">Rolston 1995</a>). </p> <p>The unit of randomisation was the patient in four trials (<a href="./references#CD003992-bbs2-0006" title="GiamarellouH , BassarisHP , PetrikkosG , BuschW , VoulgarelisM , AntoniadouA , et al. Monotherapy with intravenous followed by oral high‐dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrobial Agents and Chemotherapy2000;44:3264‐71. ">Giamarellou 2000</a>; <a href="./references#CD003992-bbs2-0010" title="KernWV , ComettaA , DeBockR , LangenaekenJ , PaesmansM , GayaH . Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. The New England Journal of Medicine1999;341:312‐8. ">Kern 1999</a>; <a href="./references#CD003992-bbs2-0011" title="MalikIA , AbbasZ , KarimM . Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet1992;339:1092‐6. ">Malik 1992</a>; <a href="./references#CD003992-bbs2-0019" title="AnaissieEJ , SamonisG , KalbakisK , GeorgouliasV . Therapy for low‐risk cancer patients with fever and neutropenia: results of a prospective, randomized trial with cost analysis. Interscience conference on antimicrobial agents and chemotherapy. 1997:LM‐51. ">Samonis 1997</a>) and the episode of febrile neutropenia in the other trials. The later trials included 2050 episodes in 1407 patients; the number of patients included was not provided in three trial (<a href="./references#CD003992-bbs2-0003" title="CornelyOA , WickeT , SeifertH , BetheU , SchwonzenM , ReichertD , et al. Once‐daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. International Journal of Hematology2004;79(1):74‐8. [MEDLINE: 14979482] ">Cornely 2003</a>; <a href="./references#CD003992-bbs2-0008" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer1999;85:213‐9. ">Hidalgo 1999</a>; <a href="./references#CD003992-bbs2-0017" title="RolstonK , RubensteinE , EltingL , EscalanteC , ManzulloE , BodeyGP . Ambulatory management of febrile episodes in low‐risk neutropenic patients. Interscience conference on antimicrobial agents and chemotherapy. 1995:LM81. ">Rolston 1995</a>). </p> <p>Graphical representation of the risk of bias is provided in <a href="#CD003992-fig-0001">Figure 1</a> and <a href="#CD003992-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD003992-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003992-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD003992-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003992-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> </section> <section id="CD003992-sec-0053"> <h3 class="title" id="CD003992-sec-0053">Effects of interventions</h3> <p>See: <a href="./full#CD003992-tbl-0001"><b>Summary of findings for the main comparison</b> Oral compared to intravenous antibiotic therapy for febrile neutropenia in cancer patients</a> </p> <section id="CD003992-sec-0054"> <h4 class="title">Mortality (9 trials, 1392 patients or episodes)</h4> <p>No difference in mortality (from any cause or caused by the infectious episode) between oral and intravenous treatment was demonstrated (RR 0.95, 95% CI 0.54 to 1.68, <a href="./references#CD003992-fig-0005" title="">Analysis 1.1</a>). </p> </section> <section id="CD003992-sec-0055"> <h4 class="title">Treatment failure (all trials, 3135 patients or episodes)</h4> <p>There was no significant difference in failure rate between the two interventions (comparison 01, outcome 02, <a href="./references#CD003992-fig-0006" title="">Analysis 1.2</a>). The RR of treatment failure for 'initial oral' studies was 0.89 (95% CI 0.79 to 1.03, N = 2189), and 1.07 (95% CI 0.90 to 1.27, N = 946) for 'sequential' studies. A comparable RR was calculated for failure not due to modification of the initial regimen.<br/> <br/> Per protocol analysis gave similar results to those of the ITT analysis (per protocol analysis: RR 0.98, 95% CI 0.86 to 1.11, all trials, 2912 patients, <a href="./references#CD003992-fig-0007" title="">Analysis 1.3</a>). </p> </section> <section id="CD003992-sec-0056"> <h4 class="title">Adverse events</h4> <p>No deaths or permanent damage were attributed to the oral therapy in any of the trials. Adverse effects that required discontinuation of the assigned antibiotic therapy were reported in 15 (<a href="./references#CD003992-bbs2-0004" title="FlahertyJP , WaitleyD , EdlinB , GeorgeD , ArnowP , O'KeefeP , et al. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. The American Journal of Medicine1989;87 Suppl:278‐82. ">Flaherty 1989</a>; <a href="./references#CD003992-bbs2-0005" title="FreifeldA , MarchigianiD , WalshT , ChanockS , LewisL , HiemenzJ , et al. A double‐blind comparison of empirical oral and intravenous antibiotic therapy for low‐risk febrile patients with neutropenia during cancer chemotherapy. The New England Journal of Medicine1999;341(5):305‐11. ">Freifeld 1999</a>; <a href="./references#CD003992-bbs2-0006" title="GiamarellouH , BassarisHP , PetrikkosG , BuschW , VoulgarelisM , AntoniadouA , et al. Monotherapy with intravenous followed by oral high‐dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrobial Agents and Chemotherapy2000;44:3264‐71. ">Giamarellou 2000</a>; <a href="./references#CD003992-bbs2-0008" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer1999;85:213‐9. ">Hidalgo 1999</a>; <a href="./references#CD003992-bbs2-0009" title="InnesHE , SmithDB , O'ReillySM , ClarkPI , KellyV , MarshallE . Oral antibiotics with early hospital discharge compared with inpatient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Data on file. ">Innes 2003</a>; <a href="./references#CD003992-bbs2-0011" title="MalikIA , AbbasZ , KarimM . Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet1992;339:1092‐6. ">Malik 1992</a>; <a href="./references#CD003992-bbs2-0012" title="MullenCA , PetropoulosD , RobertsWM , RyttingM , ZipfT , ChanKW , et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer1999;86:126‐34. MullenCA , PetropoulosD , RobertsWM , et al. Economic and resource utilization analysis of outpatient management of fever and neutropenia in low‐risk pediatric patients with cancer. Journal of Pediatric Hematology/Oncology1999;21:212‐8. ">Mullen 1999</a>; <a href="./references#CD003992-bbs2-0013" title="NihoS , OheY , GotoK , HOhmatsu , TMatsumoto , KKubota , et al. Randomized trial of oral versus intravenous antibiotics in low‐risk febrile neutropenic patients with lung cancer. Japanese Journal of Clinical Oncology2004;34(2):69‐73. [MEDLINE: 15067098] ">Niho 2004</a>; <a href="./references#CD003992-bbs2-0014" title="PaganiniHR , SarkisCM , DeMartinoMG , ZubizarretaPA , CasimirL , FernandezC , et al. Oral administration of cefixime to lower risk febrile neutropenic children with cancer. Cancer2000;88:2848‐52. ">Paganini 2000</a>; <a href="./references#CD003992-bbs2-0018" title="RubensteinEB , RolstonK , BenjaminRS , LoewyJ , EscalanteC , ManzulloE , et al. Outpatient treatment of febrile episodes in low‐risk neutropenic patients with cancer. Cancer1993;71:3640‐6. ">Rubenstein 1993</a>; <a href="./references#CD003992-bbs2-0021" title="ShenepJL , FlynnPM , BakerDK , HetheringtonSV , HudsonMM , HughesWT , et al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clinical Infectious Disease2001;32:36‐43. ">Shenep 2001</a>; <a href="./references#CD003992-bbs2-0022" title="VelascoE , CostaMA , MartinsCA , NucciM . Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients. American Journal of Clinical Oncology‐Cancer Clinical Trials1995;18(5):429‐35. ">Velasco 1995</a>) (also <a href="./references#CD003992-bbs2-0003" title="CornelyOA , WickeT , SeifertH , BetheU , SchwonzenM , ReichertD , et al. Once‐daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. International Journal of Hematology2004;79(1):74‐8. [MEDLINE: 14979482] ">Cornely 2003</a>;<a href="./references#CD003992-bbs2-0007" title="GuptaA , SwaroopC , AgarwalaS , PandeyRM , BakhshiS . Randomized controlled trial comparing oral amoxicillin‐clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low‐risk febrile neutropenia. Journal of Pediatric Hematology/Oncology2009;31(9):635‐41. ">Gupta 2009*</a>; <a href="./references#CD003992-bbs2-0010" title="KernWV , ComettaA , DeBockR , LangenaekenJ , PaesmansM , GayaH . Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. The New England Journal of Medicine1999;341:312‐8. ">Kern 1999</a>; <a href="./references#CD003992-bbs2-0015" title="PaganiniH , GomezS , RuvinskyS , ZubizarretaP , LatellaA , FraquelliL , et al. Outpatient, sequential, parenteral‐oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single‐center, randomized, controlled trial in Argentina. Cancer2003;97(7):1775–80. [MEDLINE: 12655535] ">Paganini 2003</a>; <a href="./references#CD003992-bbs2-0016" title="PetrilliAS , DantasLS , CamposMC , TanakaC , GinaniVC , SeberA . Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low‐risk pediatric oncology patients: randomized prospective trial. Medical and Pediatric Oncology2000;34:87‐91. ">Petrilli 2000</a>), which reported side effects, of the 17 trials. Separate analysis of the 'initial oral' studies revealed significantly more adverse events requiring discontinuation among orally treated patients (RR 2.78, 95% CI 1.14 to 6.75, <a href="./references#CD003992-fig-0008" title="">Analysis 1.4</a>). This finding is consistent with the high rate of gastrointestinal adverse events with oral antibiotics as shown in <a href="./references#CD003992-fig-0009" title="">Analysis 1.5</a>, and with the fact that these events hamper any oral but not intravenous treatment (<a href="./references#CD003992-bbs2-0003" title="CornelyOA , WickeT , SeifertH , BetheU , SchwonzenM , ReichertD , et al. Once‐daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. International Journal of Hematology2004;79(1):74‐8. [MEDLINE: 14979482] ">Cornely 2003</a>; <a href="./references#CD003992-bbs2-0005" title="FreifeldA , MarchigianiD , WalshT , ChanockS , LewisL , HiemenzJ , et al. A double‐blind comparison of empirical oral and intravenous antibiotic therapy for low‐risk febrile patients with neutropenia during cancer chemotherapy. The New England Journal of Medicine1999;341(5):305‐11. ">Freifeld 1999</a>; <a href="./references#CD003992-bbs2-0006" title="GiamarellouH , BassarisHP , PetrikkosG , BuschW , VoulgarelisM , AntoniadouA , et al. Monotherapy with intravenous followed by oral high‐dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrobial Agents and Chemotherapy2000;44:3264‐71. ">Giamarellou 2000</a>; <a href="./references#CD003992-bbs2-0009" title="InnesHE , SmithDB , O'ReillySM , ClarkPI , KellyV , MarshallE . Oral antibiotics with early hospital discharge compared with inpatient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Data on file. ">Innes 2003</a>; <a href="./references#CD003992-bbs2-0010" title="KernWV , ComettaA , DeBockR , LangenaekenJ , PaesmansM , GayaH . Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. The New England Journal of Medicine1999;341:312‐8. ">Kern 1999</a>; <a href="./references#CD003992-bbs2-0011" title="MalikIA , AbbasZ , KarimM . Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet1992;339:1092‐6. ">Malik 1992</a>; <a href="./references#CD003992-bbs2-0013" title="NihoS , OheY , GotoK , HOhmatsu , TMatsumoto , KKubota , et al. Randomized trial of oral versus intravenous antibiotics in low‐risk febrile neutropenic patients with lung cancer. Japanese Journal of Clinical Oncology2004;34(2):69‐73. [MEDLINE: 15067098] ">Niho 2004</a>; <a href="./references#CD003992-bbs2-0014" title="PaganiniHR , SarkisCM , DeMartinoMG , ZubizarretaPA , CasimirL , FernandezC , et al. Oral administration of cefixime to lower risk febrile neutropenic children with cancer. Cancer2000;88:2848‐52. ">Paganini 2000</a>; <a href="./references#CD003992-bbs2-0015" title="PaganiniH , GomezS , RuvinskyS , ZubizarretaP , LatellaA , FraquelliL , et al. Outpatient, sequential, parenteral‐oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single‐center, randomized, controlled trial in Argentina. Cancer2003;97(7):1775–80. [MEDLINE: 12655535] ">Paganini 2003</a>; <a href="./references#CD003992-bbs2-0016" title="PetrilliAS , DantasLS , CamposMC , TanakaC , GinaniVC , SeberA . Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low‐risk pediatric oncology patients: randomized prospective trial. Medical and Pediatric Oncology2000;34:87‐91. ">Petrilli 2000</a>; <a href="./references#CD003992-bbs2-0018" title="RubensteinEB , RolstonK , BenjaminRS , LoewyJ , EscalanteC , ManzulloE , et al. Outpatient treatment of febrile episodes in low‐risk neutropenic patients with cancer. Cancer1993;71:3640‐6. ">Rubenstein 1993</a>; <a href="./references#CD003992-bbs2-0021" title="ShenepJL , FlynnPM , BakerDK , HetheringtonSV , HudsonMM , HughesWT , et al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clinical Infectious Disease2001;32:36‐43. ">Shenep 2001</a>; <a href="./references#CD003992-bbs2-0022" title="VelascoE , CostaMA , MartinsCA , NucciM . Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients. American Journal of Clinical Oncology‐Cancer Clinical Trials1995;18(5):429‐35. ">Velasco 1995</a>) ('post‐protocol' analysis). </p> </section> <section id="CD003992-sec-0057"> <h4 class="title">Dropouts (lost to follow‐up) before end of study</h4> <p>Nineteen trials reported the number of patients who were lost to follow‐up before the end of the study in each group (<a href="./references#CD003992-bbs2-0003" title="CornelyOA , WickeT , SeifertH , BetheU , SchwonzenM , ReichertD , et al. Once‐daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. International Journal of Hematology2004;79(1):74‐8. [MEDLINE: 14979482] ">Cornely 2003</a>; <a href="./references#CD003992-bbs2-0005" title="FreifeldA , MarchigianiD , WalshT , ChanockS , LewisL , HiemenzJ , et al. A double‐blind comparison of empirical oral and intravenous antibiotic therapy for low‐risk febrile patients with neutropenia during cancer chemotherapy. The New England Journal of Medicine1999;341(5):305‐11. ">Freifeld 1999</a>; <a href="./references#CD003992-bbs2-0006" title="GiamarellouH , BassarisHP , PetrikkosG , BuschW , VoulgarelisM , AntoniadouA , et al. Monotherapy with intravenous followed by oral high‐dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrobial Agents and Chemotherapy2000;44:3264‐71. ">Giamarellou 2000</a>; <a href="./references#CD003992-bbs2-0008" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer1999;85:213‐9. ">Hidalgo 1999</a>; <a href="./references#CD003992-bbs2-0009" title="InnesHE , SmithDB , O'ReillySM , ClarkPI , KellyV , MarshallE . Oral antibiotics with early hospital discharge compared with inpatient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Data on file. ">Innes 2003</a>; <a href="./references#CD003992-bbs2-0010" title="KernWV , ComettaA , DeBockR , LangenaekenJ , PaesmansM , GayaH . Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. The New England Journal of Medicine1999;341:312‐8. ">Kern 1999</a>; <a href="./references#CD003992-bbs2-0011" title="MalikIA , AbbasZ , KarimM . Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet1992;339:1092‐6. ">Malik 1992</a>; <a href="./references#CD003992-bbs2-0013" title="NihoS , OheY , GotoK , HOhmatsu , TMatsumoto , KKubota , et al. Randomized trial of oral versus intravenous antibiotics in low‐risk febrile neutropenic patients with lung cancer. Japanese Journal of Clinical Oncology2004;34(2):69‐73. [MEDLINE: 15067098] ">Niho 2004</a>; <a href="./references#CD003992-bbs2-0014" title="PaganiniHR , SarkisCM , DeMartinoMG , ZubizarretaPA , CasimirL , FernandezC , et al. Oral administration of cefixime to lower risk febrile neutropenic children with cancer. Cancer2000;88:2848‐52. ">Paganini 2000</a>; <a href="./references#CD003992-bbs2-0015" title="PaganiniH , GomezS , RuvinskyS , ZubizarretaP , LatellaA , FraquelliL , et al. Outpatient, sequential, parenteral‐oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single‐center, randomized, controlled trial in Argentina. Cancer2003;97(7):1775–80. [MEDLINE: 12655535] ">Paganini 2003</a>; <a href="./references#CD003992-bbs2-0016" title="PetrilliAS , DantasLS , CamposMC , TanakaC , GinaniVC , SeberA . Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low‐risk pediatric oncology patients: randomized prospective trial. Medical and Pediatric Oncology2000;34:87‐91. ">Petrilli 2000</a>; <a href="./references#CD003992-bbs2-0018" title="RubensteinEB , RolstonK , BenjaminRS , LoewyJ , EscalanteC , ManzulloE , et al. Outpatient treatment of febrile episodes in low‐risk neutropenic patients with cancer. Cancer1993;71:3640‐6. ">Rubenstein 1993</a>; <a href="./references#CD003992-bbs2-0019" title="AnaissieEJ , SamonisG , KalbakisK , GeorgouliasV . Therapy for low‐risk cancer patients with fever and neutropenia: results of a prospective, randomized trial with cost analysis. Interscience conference on antimicrobial agents and chemotherapy. 1997:LM‐51. ">Samonis 1997</a>; <a href="./references#CD003992-bbs2-0021" title="ShenepJL , FlynnPM , BakerDK , HetheringtonSV , HudsonMM , HughesWT , et al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clinical Infectious Disease2001;32:36‐43. ">Shenep 2001</a>; <a href="./references#CD003992-bbs2-0022" title="VelascoE , CostaMA , MartinsCA , NucciM . Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients. American Journal of Clinical Oncology‐Cancer Clinical Trials1995;18(5):429‐35. ">Velasco 1995</a>). No significant difference in the number of dropouts was found between the oral and intravenous (IV) treatment (RR 0.82, 95% CI 0.61 to 1.10, N = 2802). </p> </section> <section id="CD003992-sec-0058"> <h4 class="title">Treatment failure ‐ age</h4> <p>The outcomes of patients younger than 60 years of age versus older patients could not be extracted from the original publications. </p> <p>There was no difference in the failure rates between the assigned treatments in the trials that included only children (RR 1.02, 95% CI 0.82 to 1.28, N = 1013, 8 trials) as well as in the trials in adults (RR 0.98, 95% CI 0.85 to 1.12, N = 1652, 12 trials, <a href="./references#CD003992-fig-0012" title="">Analysis 2.1</a>). One study (<a href="./references#CD003992-bbs2-0010" title="KernWV , ComettaA , DeBockR , LangenaekenJ , PaesmansM , GayaH . Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. The New England Journal of Medicine1999;341:312‐8. ">Kern 1999</a>) included a low number of children and was considered for the purpose of the analysis as addressing an adult population. One death was documented among children (<a href="./references#CD003992-bbs2-0001" title="BrackE , BodmerN , SimonA , LeibundgutK , KühneT , NiggliFK , et al. First‐day step‐down to oral outpatient treatment versus continued standard treatment in children with cancer and low‐risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study. Pediatric Blood &amp; Cancer2012;59(3):423‐30. LüthiF , LeibundgutK , NiggliFK , NadalD , AebiC , BodmerN , et al. Serious medical complications in children with cancer and fever in chemotherapy‐induced neutropenia: results of the prospective multicenter SPOG 2003 FN study. Pediatric Blood &amp; Cancer2012;59(1):90‐5. ">Brack 2012*</a>) treated with intravenous antibiotics. </p> </section> <section id="CD003992-sec-0059"> <h4 class="title">Treatment failure ‐ source of infection</h4> <p>Treatment failure in relation to evidence of documented infection was addressed in trials (<a href="./references#CD003992-bbs2-0005" title="FreifeldA , MarchigianiD , WalshT , ChanockS , LewisL , HiemenzJ , et al. A double‐blind comparison of empirical oral and intravenous antibiotic therapy for low‐risk febrile patients with neutropenia during cancer chemotherapy. The New England Journal of Medicine1999;341(5):305‐11. ">Freifeld 1999</a>; <a href="./references#CD003992-bbs2-0006" title="GiamarellouH , BassarisHP , PetrikkosG , BuschW , VoulgarelisM , AntoniadouA , et al. Monotherapy with intravenous followed by oral high‐dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrobial Agents and Chemotherapy2000;44:3264‐71. ">Giamarellou 2000</a>; <a href="./references#CD003992-bbs2-0008" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer1999;85:213‐9. ">Hidalgo 1999</a>; <a href="./references#CD003992-bbs2-0010" title="KernWV , ComettaA , DeBockR , LangenaekenJ , PaesmansM , GayaH . Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. The New England Journal of Medicine1999;341:312‐8. ">Kern 1999</a>; <a href="./references#CD003992-bbs2-0011" title="MalikIA , AbbasZ , KarimM . Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet1992;339:1092‐6. ">Malik 1992</a>; <a href="./references#CD003992-bbs2-0017" title="RolstonK , RubensteinE , EltingL , EscalanteC , ManzulloE , BodeyGP . Ambulatory management of febrile episodes in low‐risk neutropenic patients. Interscience conference on antimicrobial agents and chemotherapy. 1995:LM81. ">Rolston 1995</a>; <a href="./references#CD003992-bbs2-0018" title="RubensteinEB , RolstonK , BenjaminRS , LoewyJ , EscalanteC , ManzulloE , et al. Outpatient treatment of febrile episodes in low‐risk neutropenic patients with cancer. Cancer1993;71:3640‐6. ">Rubenstein 1993</a>; <a href="./references#CD003992-bbs2-0019" title="AnaissieEJ , SamonisG , KalbakisK , GeorgouliasV . Therapy for low‐risk cancer patients with fever and neutropenia: results of a prospective, randomized trial with cost analysis. Interscience conference on antimicrobial agents and chemotherapy. 1997:LM‐51. ">Samonis 1997</a>). There were no significant differences in treatment failure rate among the patients with unexplained fever (RR 1.03, 95% CI 0.79 to 1.33, N = 924) and those with documented infections (RR 1.00, 95% CI 0.84 to 1.19, N = 641, <a href="./references#CD003992-fig-0013" title="">Analysis 2.2</a>). In one trial (<a href="./references#CD003992-bbs2-0005" title="FreifeldA , MarchigianiD , WalshT , ChanockS , LewisL , HiemenzJ , et al. A double‐blind comparison of empirical oral and intravenous antibiotic therapy for low‐risk febrile patients with neutropenia during cancer chemotherapy. The New England Journal of Medicine1999;341(5):305‐11. ">Freifeld 1999</a>) the assessment was made at presentation while in the other trials assessment was done after 48 hours and therefore could not serve as a tool to assess the risk of patients ahead of treatment (unless switching to IV antibiotic treatment after 48 hours). </p> </section> <section id="CD003992-sec-0060"> <h4 class="title">Treatment failure ‐ severity of neutropenia</h4> <p>Failures according to the absolute neutrophil count (ANC) were analysed in three studies (<a href="./references#CD003992-bbs2-0010" title="KernWV , ComettaA , DeBockR , LangenaekenJ , PaesmansM , GayaH . Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. The New England Journal of Medicine1999;341:312‐8. ">Kern 1999</a>; <a href="./references#CD003992-bbs2-0018" title="RubensteinEB , RolstonK , BenjaminRS , LoewyJ , EscalanteC , ManzulloE , et al. Outpatient treatment of febrile episodes in low‐risk neutropenic patients with cancer. Cancer1993;71:3640‐6. ">Rubenstein 1993</a>; <a href="./references#CD003992-bbs2-0021" title="ShenepJL , FlynnPM , BakerDK , HetheringtonSV , HudsonMM , HughesWT , et al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clinical Infectious Disease2001;32:36‐43. ">Shenep 2001</a>). </p> <p>No significant difference in treatment failure rate was found among patients with severe neutropenia (RR 1.07, 95% CI 0.76 to 1.49, N = 370). Among patients with ANC greater than 0.1 (10<sup>9</sup> cells/L) the risk of infection was not increaed with oral antibiotics (RR 0.66, 95% CI 0.45 to 0.98, N = 328, <a href="./references#CD003992-fig-0014" title="">Analysis 2.3</a>). </p> <p>No deaths had occurred in patients with ANC greater than 0.1 (10<sup>9</sup> cells/L) at presentation. </p> </section> <section id="CD003992-sec-0061"> <h4 class="title">Treatment failure ‐ type of malignancy</h4> <p>Two trials (<a href="./references#CD003992-bbs2-0008" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer1999;85:213‐9. ">Hidalgo 1999</a>; <a href="./references#CD003992-bbs2-0019" title="AnaissieEJ , SamonisG , KalbakisK , GeorgouliasV . Therapy for low‐risk cancer patients with fever and neutropenia: results of a prospective, randomized trial with cost analysis. Interscience conference on antimicrobial agents and chemotherapy. 1997:LM‐51. ">Samonis 1997</a>) included only patients with solid tumours and patients with lymphoma. One trial (<a href="./references#CD003992-bbs2-0016" title="PetrilliAS , DantasLS , CamposMC , TanakaC , GinaniVC , SeberA . Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low‐risk pediatric oncology patients: randomized prospective trial. Medical and Pediatric Oncology2000;34:87‐91. ">Petrilli 2000</a>) included 96% patients and another trial (<a href="./references#CD003992-bbs2-0002" title="CagolAR , Castro JuniorCG , MartinsMC , MachadoAL , RibeiroRC , GregianinLJ , et al. Oral vs. intravenous empirical antimicrobial therapy in febrile neutropenic patients receiving childhood cancer chemotherapy. Jornal de Pediatria2009;85(6):531‐5. ">Cagol 2009*</a>) included 90% of patients with solid tumours and were analysed as such; two trials (<a href="./references#CD003992-bbs2-0017" title="RolstonK , RubensteinE , EltingL , EscalanteC , ManzulloE , BodeyGP . Ambulatory management of febrile episodes in low‐risk neutropenic patients. Interscience conference on antimicrobial agents and chemotherapy. 1995:LM81. ">Rolston 1995</a>; <a href="./references#CD003992-bbs2-0018" title="RubensteinEB , RolstonK , BenjaminRS , LoewyJ , EscalanteC , ManzulloE , et al. Outpatient treatment of febrile episodes in low‐risk neutropenic patients with cancer. Cancer1993;71:3640‐6. ">Rubenstein 1993</a>) provided the failure rates of both oral and intravenous treatments among patients in accordance with the background malignancy; one trial had included only haematological cancer patients (<a href="./references#CD003992-bbs2-0006" title="GiamarellouH , BassarisHP , PetrikkosG , BuschW , VoulgarelisM , AntoniadouA , et al. Monotherapy with intravenous followed by oral high‐dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrobial Agents and Chemotherapy2000;44:3264‐71. ">Giamarellou 2000</a>). No difference in treatment failure was demonstrated in patients with solid tumours (RR 0.89, 95% CI 0.70 to 1.12, N = 990) and in patients with haematological malignancy (RR 1.04, 95% CI 0.84 to 1.28, N = 312, <a href="./references#CD003992-fig-0015" title="">Analysis 2.4</a>). </p> <p>Comparison of mortality in subgroups could not be performed due to the low rate of deaths. </p> </section> <section id="CD003992-sec-0062"> <h4 class="title">Continuous data</h4> <p>Due to insufficiently reported continuous outcome data, such as duration of fever, duration of antibiotic therapy, and length of hospital stay, these data could not be analysed. </p> </section> <section id="CD003992-sec-0063"> <h4 class="title">Sensitivity and subgroup analyses</h4> <p>Sensitivity analyses of studies by the risk of bias (according to the adequacy of allocation concealment: low risk of bias, unclear; and according to blinding: blinding versus no blinding) showed no significant impact on the risk of treatment failure. Sensitivity analyses on different case definitions (trials including only patients with solid tumours versus trials including patients with solid and haematological malignancies; trials including patients with acute leukaemia versus trials excluding them; trials excluding patients with any identified source of infection at presentation versus trials including patients regardless of the source of infection; the above mentioned subgroups) showed similar RRs. </p> <section id="CD003992-sec-0064"> <h5 class="title">Treatment setting</h5> <p>Treatment setting (in or out of hospital) had no effect on the results (<a href="./references#CD003992-fig-0017" title="">Analysis 4.1</a>). </p> </section> <section id="CD003992-sec-0065"> <h5 class="title">Antibiotics used in the trials</h5> <p>Quinolones alone were tested in nine (<a href="./references#CD003992-bbs2-0003" title="CornelyOA , WickeT , SeifertH , BetheU , SchwonzenM , ReichertD , et al. Once‐daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. International Journal of Hematology2004;79(1):74‐8. [MEDLINE: 14979482] ">Cornely 2003</a>; <a href="./references#CD003992-bbs2-0004" title="FlahertyJP , WaitleyD , EdlinB , GeorgeD , ArnowP , O'KeefeP , et al. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. The American Journal of Medicine1989;87 Suppl:278‐82. ">Flaherty 1989</a>; <a href="./references#CD003992-bbs2-0006" title="GiamarellouH , BassarisHP , PetrikkosG , BuschW , VoulgarelisM , AntoniadouA , et al. Monotherapy with intravenous followed by oral high‐dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrobial Agents and Chemotherapy2000;44:3264‐71. ">Giamarellou 2000</a>; <a href="./references#CD003992-bbs2-0008" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer1999;85:213‐9. ">Hidalgo 1999</a>; <a href="./references#CD003992-bbs2-0011" title="MalikIA , AbbasZ , KarimM . Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet1992;339:1092‐6. ">Malik 1992</a>; <a href="./references#CD003992-bbs2-0012" title="MullenCA , PetropoulosD , RobertsWM , RyttingM , ZipfT , ChanKW , et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer1999;86:126‐34. MullenCA , PetropoulosD , RobertsWM , et al. Economic and resource utilization analysis of outpatient management of fever and neutropenia in low‐risk pediatric patients with cancer. Journal of Pediatric Hematology/Oncology1999;21:212‐8. ">Mullen 1999</a>; <a href="./references#CD003992-bbs2-0015" title="PaganiniH , GomezS , RuvinskyS , ZubizarretaP , LatellaA , FraquelliL , et al. Outpatient, sequential, parenteral‐oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single‐center, randomized, controlled trial in Argentina. Cancer2003;97(7):1775–80. [MEDLINE: 12655535] ">Paganini 2003</a>; <a href="./references#CD003992-bbs2-0016" title="PetrilliAS , DantasLS , CamposMC , TanakaC , GinaniVC , SeberA . Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low‐risk pediatric oncology patients: randomized prospective trial. Medical and Pediatric Oncology2000;34:87‐91. ">Petrilli 2000</a>; <a href="./references#CD003992-bbs2-0020" title="SebbanC , DussartS , FuhrmannC , GhesquieresH , RodriguesI , GeoffroisL , et al. Oral moxifloxacin or intravenous ceftriaxone for the treatment of low‐risk neutropenic fever in cancer patients suitable for early hospital discharge. Supportive Care in Cancer2008;16(9):1017‐23. ">Sebban 2009*</a>) of the 22 trials in the pooled analysis. The dosage used varied from 400 to 800 mg of ofloxacin, and 600 to 2250 mg of ciprofloxacin daily, and in one trial 400 mg moxifloxacin daily. The quinolones were most commonly used with ampicillin‐clavulanate at a maximal daily dosage of 1500 to 1875 mg. When analyses were performed according to oral antibiotic regimen, we observed no significant impact of quinolones treatment alone versus quinolones in combination with other antibiotics ('post‐protocol' analysis, <a href="./references#CD003992-fig-0018" title="">Analysis 4.2</a>). </p> </section> </section> <section id="CD003992-sec-0066"> <h4 class="title">Funnel plot asymmetry</h4> <p>No significant heterogeneity was found in any of the outcomes evaluated (<a href="#CD003992-fig-0003">Figure 3</a>, <a href="#CD003992-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD003992-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Oral versus intravenous antibiotic therapy, outcome: 1.1 Mortality." data-id="CD003992-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Oral versus intravenous antibiotic therapy, outcome: 1.1 Mortality. </p> </div> </div> </div> <div class="figure" id="CD003992-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Oral versus intravenous antibiotic therapy, outcome: 1.3 Treatment failure ‐ per protocol analysis." data-id="CD003992-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Oral versus intravenous antibiotic therapy, outcome: 1.3 Treatment failure ‐ per protocol analysis. </p> </div> </div> </div> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003992-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003992-sec-0067"></div> <p>The rates of treatment failure and mortality were not statistically significantly different in neutropenic patients given oral and intravenous antibiotic treatments. The RR for treatment failure in patients treated with oral antibiotics was 0.95. The RR for a fatal outcome was 0.95. No significant heterogeneity was shown for both comparisons. ITT analysis might favour equivalence, however the results of the per protocol analysis were similar to those of the primary analysis. </p> <p>These effects were stable in a range of patient subgroups. The RR was similar across different case definitions of the underlying disease and the cause of fever. The RR did not depend on the age of the patients or on the antibiotic regimen. It was similar in studies that started patients on immediate oral treatment and in those that switched to oral treatment after a short time of intravenous treatment. Introduction of bias by inadequate randomisation or allocation concealment was shown to be unlikely by the sensitivity analysis. There was a trend toward more adverse effects in patients given oral treatment. However the majority were gastrointestinal complaints that did not necessitate discontinuation of therapy. </p> <p>One limitation of the analysis is its inability to define the patients who may be offered oral antibiotics. This is due to the variations in the inclusion and exclusion criteria of the included trials. The difference in low risk criteria is not surprising, the concept of low risk neutropenic fever and its definition developed during the years in which the studies were performed. Different prognostic criteria evolved based on observational studies. An international collaboration had led to the development of a validated weighted scoring system identifying low risk patients, adopted by the Infectious Diseases Society of America (IDSA) (<a href="./references#CD003992-bbs2-0029" title="ChamilosG , BamiasA , EfstathiouE , ZorzouPM , KastritisE , KostisE , et al. Outpatient treatment of low‐risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer2005;103(12):2629‐35. [MEDLINE: 15856427] ">Chamilos 2005</a>; <a href="./references#CD003992-bbs2-0089" title="HughesWT , ArmstrongD , BodeyGP , BowEJ , BrownAE , CalandraT , et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectious Diseases2002;34(6):730‐51. ">Hughes 2002</a>; <a href="./references#CD003992-bbs2-0093" title="KlasterskyJ , PaesmansM , RubensteinEB , BoyerM , EltingL , FeldR , et al. The multinational association for supportive care in cancer risk index: A multinational scoring system for identifying low‐risk febrile neutropenic cancer patients. Journal of Clinical Oncology2000;18(16):3038‐51. ">Klastersky 2000</a>; <a href="./references#CD003992-bbs2-0049" title="KlasterskyJ , PaesmansM , GeorgalaA , MuanzaF , PlehiersB , DubreucqL , et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. Journal of Clinical Oncology2006;24(25):4129‐34. ">Klastersky 2006</a>). Only one of the trials added in the current version (<a href="./references#CD003992-bbs2-0020" title="SebbanC , DussartS , FuhrmannC , GhesquieresH , RodriguesI , GeoffroisL , et al. Oral moxifloxacin or intravenous ceftriaxone for the treatment of low‐risk neutropenic fever in cancer patients suitable for early hospital discharge. Supportive Care in Cancer2008;16(9):1017‐23. ">Sebban 2009*</a>) incorporated that scoring system as an inclusion criterion. </p> <p>Exclusion criteria that were common to all studies were criteria defining severe sepsis (mainly haemodynamic instability and organ failure: altered mental status, respiratory failure, renal and liver abnormalities), inability to swallow or take oral medication, allergy to study drugs, pregnancy and lactation. Most studies did not include patients with acute leukaemia and about half excluded patients with pneumonia, severe cellulitis or intravascular infection. </p> <p>The low mortality rate led to wide CIs in the absolute risk reduction. To confirm equivalence of two treatments, we should ideally be able to show that any estimate of risk that is included within the CI lies within a predefined range of equivalence (as the CI of the effect of the recommended treatment) and has no clinical significance (<a href="./references#CD003992-bbs2-0090" title="JonesB , JarvisP , LewisJA , EbbuttAF . Trials to assess equivalence: the importance of rigorous methods. BMJ1996;313(7048):36‐9. ">Jones 1996</a>). In a population with an expected mortality of less than 1% this uncertainty may have no real consequences. </p> <p>For treatment failure the CI is narrower and probably has no clinical importance since failure means mainly a change in the antibiotic regimen. </p> </section> </section> <div class="figures-list"> <div class="figure" id="CD003992-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/urn:x-wiley:14651858:media:CD003992:CD003992-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_t/tCD003992-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003992-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/full#CD003992-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003992-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/urn:x-wiley:14651858:media:CD003992:CD003992-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_t/tCD003992-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003992-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/full#CD003992-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003992-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/urn:x-wiley:14651858:media:CD003992:CD003992-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_t/tCD003992-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Oral versus intravenous antibiotic therapy, outcome: 1.1 Mortality." data-id="CD003992-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Oral versus intravenous antibiotic therapy, outcome: 1.1 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/full#CD003992-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003992-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/urn:x-wiley:14651858:media:CD003992:CD003992-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_t/tCD003992-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Oral versus intravenous antibiotic therapy, outcome: 1.3 Treatment failure ‐ per protocol analysis." data-id="CD003992-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Oral versus intravenous antibiotic therapy, outcome: 1.3 Treatment failure ‐ per protocol analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/full#CD003992-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003992-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/urn:x-wiley:14651858:media:CD003992:CD003992-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_t/tCD003992-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral versus intravenous antibiotic therapy, Outcome 1 Mortality." data-id="CD003992-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Oral versus intravenous antibiotic therapy, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/references#CD003992-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003992-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/urn:x-wiley:14651858:media:CD003992:CD003992-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_t/tCD003992-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral versus intravenous antibiotic therapy, Outcome 2 Treatment failure." data-id="CD003992-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Oral versus intravenous antibiotic therapy, Outcome 2 Treatment failure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/references#CD003992-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003992-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/urn:x-wiley:14651858:media:CD003992:CD003992-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_t/tCD003992-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral versus intravenous antibiotic therapy, Outcome 3 Treatment failure ‐ per protocol analysis." data-id="CD003992-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Oral versus intravenous antibiotic therapy, Outcome 3 Treatment failure ‐ per protocol analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/references#CD003992-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003992-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/urn:x-wiley:14651858:media:CD003992:CD003992-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_t/tCD003992-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral versus intravenous antibiotic therapy, Outcome 4 Adverse events requiring discontinuation of antibiotics." data-id="CD003992-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Oral versus intravenous antibiotic therapy, Outcome 4 Adverse events requiring discontinuation of antibiotics. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/references#CD003992-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003992-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/urn:x-wiley:14651858:media:CD003992:CD003992-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_t/tCD003992-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral versus intravenous antibiotic therapy, Outcome 5 Gastrointestinal adverse events ('post‐protocol' analysis)." data-id="CD003992-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Oral versus intravenous antibiotic therapy, Outcome 5 Gastrointestinal adverse events ('post‐protocol' analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/references#CD003992-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003992-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/urn:x-wiley:14651858:media:CD003992:CD003992-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_t/tCD003992-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral versus intravenous antibiotic therapy, Outcome 6 Lost to follow‐up." data-id="CD003992-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Oral versus intravenous antibiotic therapy, Outcome 6 Lost to follow‐up.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/references#CD003992-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003992-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/urn:x-wiley:14651858:media:CD003992:CD003992-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_t/tCD003992-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral versus intravenous antibiotic therapy, Outcome 7 Treatment failure not dt modification in update." data-id="CD003992-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Oral versus intravenous antibiotic therapy, Outcome 7 Treatment failure not dt modification in update. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/references#CD003992-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003992-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/urn:x-wiley:14651858:media:CD003992:CD003992-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_t/tCD003992-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oral versus intravenous antibiotic therapy ‐ subgroup analysis, Outcome 1 Treatment failure ‐ age." data-id="CD003992-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Oral versus intravenous antibiotic therapy ‐ subgroup analysis, Outcome 1 Treatment failure ‐ age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/references#CD003992-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003992-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/urn:x-wiley:14651858:media:CD003992:CD003992-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_t/tCD003992-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oral versus intravenous antibiotic therapy ‐ subgroup analysis, Outcome 2 Treatment failure ‐ source of infection." data-id="CD003992-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Oral versus intravenous antibiotic therapy ‐ subgroup analysis, Outcome 2 Treatment failure ‐ source of infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/references#CD003992-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003992-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/urn:x-wiley:14651858:media:CD003992:CD003992-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_t/tCD003992-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oral versus intravenous antibiotic therapy ‐ subgroup analysis, Outcome 3 Treatment failure ‐ severity of neutropenia." data-id="CD003992-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Oral versus intravenous antibiotic therapy ‐ subgroup analysis, Outcome 3 Treatment failure ‐ severity of neutropenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/references#CD003992-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003992-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/urn:x-wiley:14651858:media:CD003992:CD003992-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_t/tCD003992-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oral versus intravenous antibiotic therapy ‐ subgroup analysis, Outcome 4 Treatment failure ‐ type of malignancy." data-id="CD003992-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Oral versus intravenous antibiotic therapy ‐ subgroup analysis, Outcome 4 Treatment failure ‐ type of malignancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/references#CD003992-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003992-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/urn:x-wiley:14651858:media:CD003992:CD003992-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_t/tCD003992-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Methodological quality of studies, Outcome 1 Allocation concealment." data-id="CD003992-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Methodological quality of studies, Outcome 1 Allocation concealment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/references#CD003992-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003992-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/urn:x-wiley:14651858:media:CD003992:CD003992-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_t/tCD003992-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Post hoc subgroup analyses, Outcome 1 Setting." data-id="CD003992-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Post hoc subgroup analyses, Outcome 1 Setting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/references#CD003992-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003992-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/urn:x-wiley:14651858:media:CD003992:CD003992-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_t/tCD003992-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Post hoc subgroup analyses, Outcome 2 Type of oral antibiotics." data-id="CD003992-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Post hoc subgroup analyses, Outcome 2 Type of oral antibiotics.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/references#CD003992-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/media/CDSR/CD003992/image_n/nCD003992-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003992-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oral compared to intravenous antibiotic therapy for febrile neutropenia in cancer patients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral compared to intravenous antibiotic therapy for febrile neutropenia in cancer patients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with febrile neutropenia in cancer patients<br/> <b>Settings:</b> <br/> <b>Intervention:</b> oral<br/> <b>Comparison:</b> intravenous antibiotic therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> intravenous antibiotic therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Oral</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.95</b> <br/> (0.54 to 1.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1392<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 1000</b> <br/> (17 to 54) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Low risk</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment failure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.96</b> <br/> (0.86 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3142<br/> (22 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>284 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>272 per 1000</b> <br/> (244 to 301) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>211 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>203 per 1000</b> <br/> (181 to 224) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment failure ‐ per protocol analysis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.98</b> <br/> (0.86 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2912<br/> (22 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>225 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>221 per 1000</b> <br/> (194 to 250) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>184 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>180 per 1000</b> <br/> (158 to 204) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events requiring discontinuation of antibiotics</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.45</b> <br/> (0.61 to 3.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1823<br/> (15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> <br/> (13 to 73) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment failure not dt modification in update</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.95</b> <br/> (0.85 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3041<br/> (21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>267 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>254 per 1000</b> <br/> (227 to 283) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>180 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>171 per 1000</b> <br/> (153 to 191) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> High risk of detection bias in most of the trials </p> <p><sup>2</sup> A wide CI </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oral compared to intravenous antibiotic therapy for febrile neutropenia in cancer patients</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/full#CD003992-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003992-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Criteria for low risk patients (as defined in most included studies)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Common criteria</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haemodynamic stablity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No organ failure</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ability to take oral medications</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No pneumonia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No infection of a central line</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No severe soft‐tissue infection</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No acute leukaemia as the background malignancy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No known drug allergy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not pregnant or lactating women</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Criteria for low risk patients (as defined in most included studies)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/full#CD003992-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003992-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Exclusion criteria of included trials (2004)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Evident infection</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Previous AB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Prolonged neutropeni</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Performance status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Active malignancy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BMT/PSCT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Other</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kern 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infected catheter or CNS infection, known bacterial /viral/fungal infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need of IV supportive therapy, expected to die within 48 hours, HIV, fever unrelated to infection and protocol violation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mullen 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A source of infection that required hospitalisation as: tunnelitis, pneumonia, perirectal cellulitis, typhlitis, resistant microorganism to one of the study's drugs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt;10% dehydration, bleeding requiring platelet transfusion,<br/> need for IV access, no access to telephone, &gt;1hour away from hospital unreliable caretaker </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paganini 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infected catheter, perineal/ facial cellulitis, uncontrolled local infection, positive blood cultures at 72 hours </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Persistance of fever &gt;48 hours, incorrectable bleeding; refractory hypoglycemia or hypocalcemia </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rubenstein 1993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Known resistant microorganism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na&lt;128, uncontrolled hypercalcemia, more than 30 miles away</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Samonis 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pneumonia, deep organ infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prior hospitalisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shenep 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pneumonia, clinical or radiographic evidence of focal bacterial infection, severe mucositis, positive blood cultures at 48 hours </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MRSA or P.Aeroginosa in any culture obtained in preceding 12weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Velasco1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Meningitis, pyelonephritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term central vein catheter</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Petrilli 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flaherty 1989</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Freifeld 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intravascular infection, tunnelitis, pneumonia, neurologic symtoms,</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment with Ca‐Mg or probenecid or alluporinol or theophylline, HIV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Giamarelou 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Suspected anaerobes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moribund and high probability of dying within 48 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hidalgo 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pneumonia, extensive cellulitis, meningitis, pyelonephritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clotting abnormalities, acidosis, hypercalcaemia, uncontrolled bleeding, live &gt;2h apart from hospital; Hx of tumour fever, other severe extra hematologic chemotherapy induced toxicity, no 24 hours home companion </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Innes 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tunnelitis, cellulitis, abcess, clinically documented infection likely to require prolonged antibiotic therapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for the use of G/GM‐CSF and cytokines; no responsible adult living with them (carer); </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Malik 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent FUO</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cornely 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excluded (except cotrimoxazole prophylaxis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>potential compromised absorption; inability to take oral medication; tenopathy, epilepsy; aplastic anaemia, acute leukaemia; septic shock or signs of sever infection; HIV carrier; serious concomitant disease, liver transaminase&gt; x5 of norm. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Niho 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent FUO; renal insufficiency; hepatic insufficiency; hypotension or peripheral circulatory failure; uncontrolled hypercalcaemia; altered sensorium; respiratory rate &gt;30 breaths/min; serum sodium &lt;128 mg/dl; inability to take oral medications; intestinal malabsorption </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paganini 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fascial, perineal, or catheter‐associated cellulites; uncontrolled local infection; positive blood cultures within the first 48 hours; infection with microorganisms known as resistant to ceftriaxone or ciprofloxacin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>severe comorbidity factors; respiratory failure</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Exclusion criteria of included trials (2004)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/full#CD003992-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003992-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oral versus intravenous antibiotic therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.54, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Initially oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>961</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.43, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Sequential</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.45, 4.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.86, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Initially oral treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.79, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Sequential IV to oral treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>946</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.90, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Treatment failure ‐ per protocol analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2912</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.86, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Initially oral treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.78, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Sequential IV to oral treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.88, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events requiring discontinuation of antibiotics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1823</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.61, 3.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Initially oral treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1064</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.78 [1.14, 6.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Sequential IV to oral treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.26, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Gastrointestinal adverse events ('post‐protocol' analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Initially oral treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.49 [2.87, 7.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Sequential IV to oral treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>784</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.81 [1.03, 7.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Lost to follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2810</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.61, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Treatment failure not dt modification in update <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3041</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.85, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Initially oral treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2095</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.79, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Sequential IV to oral treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>946</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.88, 1.25]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oral versus intravenous antibiotic therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/references#CD003992-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003992-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oral versus intravenous antibiotic therapy ‐ subgroup analysis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Treatment failure ‐ age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.82, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.85, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Treatment failure ‐ source of infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Unexplained fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>924</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.79, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Documented infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>641</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.84, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Treatment failure ‐ severity of neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Absolute neutrophil count &gt;=10^9/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.45, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Absolute neutrophil count &lt;10^9/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.76, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Treatment failure ‐ type of malignancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Solid tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.70, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Haemetologic malignancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.84, 1.28]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oral versus intravenous antibiotic therapy ‐ subgroup analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/references#CD003992-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003992-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Methodological quality of studies</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Allocation concealment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Adequate (A)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.81, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Unclear (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.84, 1.14]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Methodological quality of studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/references#CD003992-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003992-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Post hoc subgroup analyses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Setting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Oral‐outpatient, IV‐inpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.63, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Inpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.81, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>816</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.85, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Only first dose in</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.41, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Type of oral antibiotics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Quinolones only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.88, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Quinolones in combination with augmentin, ampicillin‐sulbactam, penicillin V or clindamycin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1679</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.76, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Cefixime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.64, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 New quinolones</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.50, 1.86]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Post hoc subgroup analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003992.pub3/references#CD003992-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003992.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003992-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003992-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003992-note-0001">Français</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003992\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003992\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003992\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003992\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003992\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003992\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003992\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003992\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003992\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003992\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003992\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003992\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003992\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003992\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003992\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003992\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003992\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003992\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=zCmos3jT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003992.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003992.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003992.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003992.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003992.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725459387"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003992.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725459391"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003992.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e7bc28809f4b8',t:'MTc0MDcyNTQ1OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 